{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":898,"total_is_capped":false,"direct_labels_cover":3,"predictions_cover":898,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"072571263395","filters":{"topic":"Advanced Breast Cancer Therapies"}},"results":[{"id":"W2552099557","doi":"10.1056/nejmoa1607303","title":"Palbociclib and Letrozole in Advanced Breast Cancer","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2948,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Palbociclib; Letrozole; Medicine; Breast cancer; Oncology; Estrogen receptor; Internal medicine; Cancer; Gynecology; Metastatic breast cancer; Tamoxifen","authors":[{"name":"Richard S. Finn","is_ca":false},{"name":"Miguel Martín","is_ca":false},{"name":"Hope S. Rugo","is_ca":false},{"name":"Stephen E. Jones","is_ca":false},{"name":"Seock‐Ah Im","is_ca":false},{"name":"Karen A. Gelmon","is_ca":true},{"name":"Nadia Harbeck","is_ca":false},{"name":"Oleg Lipatov","is_ca":false},{"name":"Janice M. Walshe","is_ca":false},{"name":"Stacy Moulder","is_ca":false},{"name":"Eric Gauthier","is_ca":false},{"name":"Dongrui R. Lu","is_ca":false},{"name":"Sophia Randolph","is_ca":false},{"name":"Véronique Dièras","is_ca":false},{"name":"Dennis J. Slamon","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01120009148616708,"gpt":0.2938672739258823,"spread":0.2826671824397152,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001199891,0.0003835005,0.001067089,0.0004152374,0.0001367708,0.0003252085,0.0003479334,0.0005005625,0.002681037],"category_scores_gemma":[0.001192057,0.000166054,0.0004891085,0.0003433391,0.0003732562,0.0002394527,0.0002360678,0.001043402,0.0002995909],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004625659,"about_ca_system_score_gemma":0.0006939162,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004691325,"about_ca_topic_score_gemma":0.0009839531,"domain_scores_codex":[0.9995549,0.0002474073,0.00002611013,0.00005014457,0.00008863845,0.00003280665],"domain_scores_gemma":[0.9995833,0.0001867398,0.00009651155,0.00001734143,0.00002287422,0.00009322952],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4718374,0.008765409,0.01198968,0.002934414,0.001833119,0.0003069819,0.0001221852,0.002698619,0.02944209,0.0006270912,0.002826896,0.466616],"study_design_scores_gemma":[0.5737056,0.3372,0.05433339,0.0004318273,0.002236654,0.001073861,0.00006106713,0.002621463,0.009772726,0.00107482,0.01744935,0.00003910567],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9491668,0.04402475,0.0007974302,0.001080472,0.0002139465,0.0008612997,0.0003494975,0.00006733199,0.003438518],"genre_scores_gemma":[0.9862699,0.0102078,0.0009618148,0.0005360141,0.0002006881,0.0004237011,0.0003146404,0.000005750411,0.001079703],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002681037,"threshold_uncertainty_score":0.008969009,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2290950904","doi":"10.1016/s1470-2045(15)00613-0","title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1822,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre; University of Calgary","funders":"University of California, Los Angeles; Novartis; Daiichi-Sankyo; Pfizer; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline; U.S. Department of Defense","keywords":"Fulvestrant; Palbociclib; Metastatic breast cancer; Medicine; Placebo; Internal medicine; Oncology; Gynecology; Cancer; Breast cancer; Estrogen receptor","authors":[{"name":"Massimo Cristofanilli","is_ca":false},{"name":"Nicholas C. Turner","is_ca":false},{"name":"Igor Bondarenko","is_ca":false},{"name":"Jungsil Ro","is_ca":false},{"name":"Seock‐Ah Im","is_ca":false},{"name":"Norikazu Masuda","is_ca":false},{"name":"Marco Colleoni","is_ca":false},{"name":"Angela DeMichele","is_ca":false},{"name":"Sherene Loi","is_ca":false},{"name":"Sunil Verma","is_ca":true},{"name":"Hiroji Iwata","is_ca":false},{"name":"Nadia Harbeck","is_ca":false},{"name":"Ke Zhang","is_ca":false},{"name":"Kathy Puyana Theall","is_ca":false},{"name":"Yuqiu Jiang","is_ca":false},{"name":"Cynthia Huang Bartlett","is_ca":false},{"name":"María Koehler","is_ca":false},{"name":"Dennis J. Slamon","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1235990477317247,"gpt":0.4149209742192354,"spread":0.2913219264875107,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002516419,0.002579488,0.003969922,0.0005987741,0.0004052526,0.001291883,0.001357067,0.001918248,0.008257579],"category_scores_gemma":[0.002715634,0.0007694033,0.003839853,0.0005486463,0.001387201,0.001594343,0.0005516667,0.00348331,0.00120975],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001071077,"about_ca_system_score_gemma":0.001029497,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00165235,"about_ca_topic_score_gemma":0.003537167,"domain_scores_codex":[0.9990838,0.0005325862,0.00005834198,0.0001425142,0.00005108925,0.0001316262],"domain_scores_gemma":[0.9990283,0.0003794587,0.0002279654,0.00009109511,0.00005873504,0.0002144248],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9918806,0.0006768257,0.00008925319,0.0005579384,0.0008320248,0.00001315231,0.00002136042,0.0001700934,0.0007900264,0.00005625146,0.0002629912,0.004649439],"study_design_scores_gemma":[0.9849277,0.01371717,0.0003925062,0.00002493217,0.0003705115,0.00001063229,0.00001045584,0.0001669237,0.00009949099,0.00009213231,0.0001793921,0.000008164335],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9691883,0.01538618,0.001928907,0.001315055,0.00176379,0.005205363,0.002014484,0.0003884335,0.002809467],"genre_scores_gemma":[0.9828025,0.00474521,0.001950554,0.001082356,0.0005702908,0.003742935,0.001040534,0.00005032662,0.004015274],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008257579,"threshold_uncertainty_score":0.02762431,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2057272791","doi":"10.1038/nrd4504","title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","year":2015,"lang":"en","type":"review","venue":"Nature Reviews Drug Discovery","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1762,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Cancer Institute; Consortium canadien en neurodégénérescence associée au vieillissement; Cancer Research UK; F. Hoffmann-La Roche; Bristol-Myers Squibb","keywords":"Kinase; Cyclin; Cancer research; Targeted therapy; Cancer; Cyclin-dependent kinase; Cancer therapy; Medicine; Oncology; Biology; Internal medicine; Cell biology; Cell cycle","authors":[{"name":"Uzma Asghar","is_ca":false},{"name":"Agnieszka K. Witkiewicz","is_ca":false},{"name":"Nicholas C. Turner","is_ca":false},{"name":"Erik S. Knudsen","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04203717735178965,"gpt":0.3749503544363558,"spread":0.3329131770845662,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001136958,0.0006443682,0.001263208,0.001805689,0.0003873144,0.001503154,0.001009108,0.001440241,0.0045728],"category_scores_gemma":[0.001464017,0.0003141279,0.0005104652,0.001935498,0.001235304,0.002372933,0.001011512,0.003153369,0.001910624],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001094939,"about_ca_system_score_gemma":0.001385825,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001335603,"about_ca_topic_score_gemma":0.003769091,"domain_scores_codex":[0.9997222,0.00006292481,0.00002519717,0.00003811984,0.0001152038,0.00003635656],"domain_scores_gemma":[0.9993634,0.0003708357,0.00005919416,0.00001817994,0.0001301207,0.00005835084],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001464279,0.00008634078,0.000190758,0.01240585,0.00006711222,0.0002078022,0.0001057464,0.0006260295,0.003112602,0.01446945,0.0542708,0.9143111],"study_design_scores_gemma":[0.00001724566,0.00005206915,0.0002257508,0.001410817,0.00004355609,0.0003514631,0.00004145353,0.0001256196,0.0003987726,0.003801569,0.9935191,0.00001264202],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00008165374,0.9978472,0.0001628797,0.0006619378,0.0002462287,0.000002864778,0.00001222798,0.000007154577,0.0009779036],"genre_scores_gemma":[0.0009173162,0.9975648,0.0002059283,0.0004920671,0.0002679666,0.000003923071,0.00001476263,0.000001816876,0.0005315103],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.0045728,"threshold_uncertainty_score":0.01529759,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1464936406","doi":"10.1056/nejmoa1505270","title":"Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1586,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Fulvestrant; Palbociclib; Medicine; Internal medicine; Oncology; Breast cancer; Hazard ratio; Exemestane; Clinical endpoint; Neutropenia; Placebo; Cancer; Metastatic breast cancer; Clinical trial; Estrogen receptor; Confidence interval; Chemotherapy; Tamoxifen; Pathology","authors":[{"name":"Nicholas C. Turner","is_ca":false},{"name":"Jungsil Ro","is_ca":false},{"name":"Fabrice André","is_ca":false},{"name":"Sherene Loi","is_ca":false},{"name":"Sunil Verma","is_ca":true},{"name":"Hiroji Iwata","is_ca":false},{"name":"Nadia Harbeck","is_ca":false},{"name":"Sibylle Loibl","is_ca":false},{"name":"Cynthia Huang Bartlett","is_ca":false},{"name":"Ke Zhang","is_ca":false},{"name":"C. Giorgetti","is_ca":false},{"name":"Sophia Randolph","is_ca":false},{"name":"María Koehler","is_ca":false},{"name":"Massimo Cristofanilli","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01997212785007568,"gpt":0.3116514899941887,"spread":0.2916793621441131,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001884273,0.0004617159,0.0009867615,0.0002986626,0.0001404227,0.000399872,0.0004911614,0.0003944036,0.002440599],"category_scores_gemma":[0.001046032,0.0001348965,0.0005456429,0.0004478287,0.0003695629,0.0002548472,0.0002369457,0.001343132,0.0003426367],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007387105,"about_ca_system_score_gemma":0.0008084495,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008887127,"about_ca_topic_score_gemma":0.001633444,"domain_scores_codex":[0.9995535,0.0002611357,0.00002398864,0.00004192064,0.00007298626,0.00004644508],"domain_scores_gemma":[0.9993764,0.0002965547,0.0001292112,0.00002355735,0.00004372876,0.0001305692],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3075694,0.006162496,0.03248898,0.003805821,0.002071054,0.0007932136,0.0001888438,0.008326773,0.02524329,0.0008229252,0.009927599,0.6025996],"study_design_scores_gemma":[0.4779657,0.2767511,0.155647,0.001089875,0.00472255,0.003101252,0.0001980109,0.009795113,0.0134307,0.002642588,0.05458042,0.00007582745],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9238576,0.06402872,0.001131754,0.002328543,0.0002646635,0.00097919,0.0007130063,0.0001054862,0.006591238],"genre_scores_gemma":[0.9801615,0.0160187,0.0007974224,0.0008348558,0.0002611175,0.0003820375,0.0006428174,0.00001307567,0.0008884715],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002440599,"threshold_uncertainty_score":0.009965062,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4206666777","doi":"10.1016/j.annonc.2020.09.010","title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1356,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"European Society for Medical Oncology; Novo Nordisk Fonden; European School of Oncology","keywords":"Medicine; Guideline; Multidisciplinary approach; Breast cancer; Expert opinion; Clinical Practice; Medical physics; Intensive care medicine; Cancer; Family medicine; Internal medicine; Pathology","authors":[{"name":"Fátima Cardoso","is_ca":false},{"name":"Shani Paluch–Shimon","is_ca":false},{"name":"Elżbieta Senkus","is_ca":false},{"name":"Giuseppe Curigliano","is_ca":false},{"name":"Matti Aapro","is_ca":false},{"name":"Fabrice André","is_ca":false},{"name":"C.H. Barrios","is_ca":false},{"name":"Jonas Bergh","is_ca":false},{"name":"G.S. Bhattacharyya","is_ca":false},{"name":"Laura Biganzoli","is_ca":false},{"name":"Frances Boyle","is_ca":false},{"name":"Maria João Cardoso","is_ca":false},{"name":"L.A. Carey","is_ca":false},{"name":"Javier Cortés","is_ca":false},{"name":"Nagi S. El Saghir","is_ca":false},{"name":"Mona Elzayat","is_ca":false},{"name":"Alexandru Eniu","is_ca":false},{"name":"Lesley Fallowfield","is_ca":false},{"name":"Prudence A. Francis","is_ca":false},{"name":"Karen A. Gelmon","is_ca":true},{"name":"Joseph Gligorov","is_ca":false},{"name":"Renate Haidinger","is_ca":false},{"name":"Nadia Harbeck","is_ca":false},{"name":"Xin Hu","is_ca":false},{"name":"Bella Kaufman","is_ca":false},{"name":"Rajneesh Kaur","is_ca":false},{"name":"Belinda E. Kiely","is_ca":false},{"name":"S.-B. Kim","is_ca":false},{"name":"NU Lin","is_ca":false},{"name":"Shirley Mertz","is_ca":false},{"name":"Silvia P. Neciosup","is_ca":false},{"name":"B.V. Offersen","is_ca":false},{"name":"Shinji Ohno","is_ca":false},{"name":"Olivia Pagani","is_ca":false},{"name":"A. Prat","is_ca":false},{"name":"Frédérique Penault‐Llorca","is_ca":false},{"name":"Hope S. Rugo","is_ca":false},{"name":"G. W. Sledge","is_ca":false},{"name":"Christoph Thomssen","is_ca":false},{"name":"D.A. Vorobiof","is_ca":false},{"name":"Theresa Wiseman","is_ca":false},{"name":"Binghe Xu","is_ca":false},{"name":"Larry Norton","is_ca":false},{"name":"A. Costa","is_ca":false},{"name":"Eric P. Winer","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2443267065097386,"gpt":0.5038172245427751,"spread":0.2594905180330365,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007857543,0.001104133,0.001326681,0.004471803,0.001011046,0.002705848,0.003725181,0.004987587,0.02396294],"category_scores_gemma":[0.01934446,0.0005842702,0.003027652,0.002117066,0.0007940204,0.001584138,0.003011119,0.004545106,0.01753645],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003113797,"about_ca_system_score_gemma":0.01043586,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006988018,"about_ca_topic_score_gemma":0.01134412,"domain_scores_codex":[0.99401,0.002159077,0.0009783934,0.0002554208,0.002139638,0.0004575202],"domain_scores_gemma":[0.9909956,0.001579943,0.000993207,0.0002602262,0.005443363,0.0007277901],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001310911,0.0000947736,0.001079187,0.003869046,0.0000932855,0.0003123423,0.0001462648,0.000533908,0.0004239744,0.005466386,0.7713319,0.2165178],"study_design_scores_gemma":[0.00006902286,0.00005769194,0.001715274,0.009120545,0.0001065995,0.0007365366,0.0001121613,0.0001974,0.0002064196,0.002884972,0.9847679,0.00002568214],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"methods","genre_scores_codex":[0.004672511,0.4352327,0.03304463,0.2213321,0.04668434,0.004842084,0.02399218,0.002310353,0.227889],"genre_scores_gemma":[0.04041957,0.4454982,0.1534749,0.1040589,0.01498752,0.01140459,0.08655718,0.001338797,0.1422604],"genre_candidate":"methods","genre_consensus":null,"teacher_disagreement_score":0.02396294,"threshold_uncertainty_score":0.08016402,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4239051461","doi":"10.1093/annonc/mdy192","title":"4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1190,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Breast cancer; Oncology; Consensus conference; Medical physics; Cancer; Family medicine; Internal medicine","authors":[{"name":"Fátima Cardoso","is_ca":false},{"name":"Elżbieta Senkus","is_ca":false},{"name":"A. Costa","is_ca":false},{"name":"Efthymios Papadopoulos","is_ca":false},{"name":"Matti Aapro","is_ca":false},{"name":"Fabrice André","is_ca":false},{"name":"Nadia Harbeck","is_ca":false},{"name":"B. Aguilar Lopez","is_ca":false},{"name":"C.H. Barrios","is_ca":false},{"name":"Jonas Bergh","is_ca":false},{"name":"Laura Biganzoli","is_ca":false},{"name":"C.B. Boers-Doets","is_ca":false},{"name":"Maria João Cardoso","is_ca":false},{"name":"L.A. Carey","is_ca":false},{"name":"Javier Cortés","is_ca":false},{"name":"Giuseppe Curigliano","is_ca":false},{"name":"Véronique Dièras","is_ca":false},{"name":"Nagi S. El Saghir","is_ca":false},{"name":"Alexandru Eniu","is_ca":false},{"name":"Lesley Fallowfield","is_ca":false},{"name":"P.A. Francis","is_ca":false},{"name":"Karen A. Gelmon","is_ca":true},{"name":"S. Johnston","is_ca":false},{"name":"Bella Kaufman","is_ca":false},{"name":"Smruti Koppikar","is_ca":false},{"name":"I.E. Krop","is_ca":false},{"name":"Musa Mayer","is_ca":false},{"name":"Gertrude Nakigudde","is_ca":false},{"name":"B.V. Offersen","is_ca":false},{"name":"Shinji Ohno","is_ca":false},{"name":"Olivia Pagani","is_ca":false},{"name":"Shani Paluch–Shimon","is_ca":false},{"name":"Frédérique Penault‐Llorca","is_ca":false},{"name":"Aleix Prat","is_ca":false},{"name":"H.S. Rugo","is_ca":false},{"name":"G. W. Sledge","is_ca":false},{"name":"Danielle Spence","is_ca":false},{"name":"Christoph Thomssen","is_ca":false},{"name":"D.A. Vorobiof","is_ca":false},{"name":"B. Xu","is_ca":false},{"name":"Larry Norton","is_ca":false},{"name":"E.P. Winer","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1732144412306442,"gpt":0.5044417495037564,"spread":0.3312273082731122,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01488704,0.00212375,0.002698703,0.01208642,0.001392478,0.004006705,0.006444987,0.005630826,0.01475497],"category_scores_gemma":[0.04092903,0.001232565,0.006139319,0.006311592,0.001359104,0.002326476,0.003874933,0.006738598,0.01470053],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.006283453,"about_ca_system_score_gemma":0.02090284,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01934732,"about_ca_topic_score_gemma":0.02058498,"domain_scores_codex":[0.9868542,0.004397435,0.002558566,0.0006208952,0.004661226,0.0009076559],"domain_scores_gemma":[0.9753875,0.004508326,0.002684703,0.0006509469,0.01557233,0.0011963],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001694632,0.00007584444,0.001622722,0.007041596,0.0001700474,0.000255962,0.0002367508,0.0007646707,0.0004426556,0.003432191,0.8369619,0.1488262],"study_design_scores_gemma":[0.0001420021,0.00006656835,0.003490039,0.02293843,0.000310012,0.000880257,0.0003366389,0.0004736875,0.0004969023,0.003891111,0.9669047,0.00006951135],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"methods","genre_scores_codex":[0.004326422,0.5436352,0.04593273,0.1806869,0.04650345,0.008133471,0.05676466,0.003418439,0.1105988],"genre_scores_gemma":[0.03435956,0.4753993,0.1729094,0.04940031,0.01194329,0.0172349,0.1556614,0.001980661,0.08111127],"genre_candidate":"methods","genre_consensus":null,"teacher_disagreement_score":0.01934732,"threshold_uncertainty_score":0.07873112,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2804105316","doi":"10.1016/s1470-2045(18)30292-4","title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1011,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Ottawa","funders":"Astex Pharmaceuticals; Novartis","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Hormone receptor; Endocrine system; Hormone therapy; Gynecology; Cancer; Hormone","authors":[{"name":"Debu Tripathy","is_ca":false},{"name":"Seock‐Ah Im","is_ca":false},{"name":"Marco Colleoni","is_ca":false},{"name":"Fábio Franke","is_ca":false},{"name":"Aditya Bardia","is_ca":false},{"name":"Nadia Harbeck","is_ca":false},{"name":"Sara A. Hurvitz","is_ca":false},{"name":"Louis W.C. Chow","is_ca":false},{"name":"Joohyuk Sohn","is_ca":false},{"name":"Keun Seok Lee","is_ca":false},{"name":"Saúl Campos-Gómez","is_ca":false},{"name":"Rafael Villanueva-Vázquez","is_ca":false},{"name":"Kyung Hae Jung","is_ca":false},{"name":"Govind Babu","is_ca":false},{"name":"Paul Wheatley‐Price","is_ca":true},{"name":"Michelino De Laurentiis","is_ca":false},{"name":"Young‐Hyuck Im","is_ca":false},{"name":"Sherko Küemmel","is_ca":false},{"name":"Nagi S. El-Saghir","is_ca":false},{"name":"Mei-Ching Liu","is_ca":false},{"name":"Gary P. Carlson","is_ca":false},{"name":"Gareth Hughes","is_ca":false},{"name":"Iván Díaz-Padilla","is_ca":false},{"name":"Caroline Germa","is_ca":false},{"name":"Samit Hirawat","is_ca":false},{"name":"Yen‐Shen Lu","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03244725651231038,"gpt":0.3715379082167767,"spread":0.3390906517044663,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00128093,0.001520973,0.002249221,0.0003647828,0.0003501467,0.001013981,0.0009013261,0.00171137,0.01081094],"category_scores_gemma":[0.001387945,0.0005725081,0.002418379,0.0003809478,0.0009553131,0.0008610016,0.0005038374,0.003252038,0.001952367],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008575195,"about_ca_system_score_gemma":0.001091216,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001872325,"about_ca_topic_score_gemma":0.006678168,"domain_scores_codex":[0.9996374,0.0001801997,0.00001473805,0.0000571874,0.00002735649,0.00008304657],"domain_scores_gemma":[0.9995239,0.0001369125,0.00007237974,0.00004567555,0.00002789953,0.0001933247],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9638402,0.003143784,0.0006164248,0.001054655,0.001732935,0.00006409686,0.00006090074,0.0004692136,0.002447357,0.0002248183,0.003085553,0.02325999],"study_design_scores_gemma":[0.9682809,0.02804646,0.001207702,0.00004412474,0.0005235228,0.00004311722,0.00002651235,0.0001890975,0.0001237519,0.0001958062,0.001306857,0.00001219068],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9504369,0.02539359,0.0008993712,0.003009056,0.001753179,0.005027988,0.004235759,0.0003420038,0.008901997],"genre_scores_gemma":[0.9533215,0.01319192,0.001962294,0.004401722,0.0009019407,0.006029165,0.005059229,0.00007789171,0.01505444],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01081094,"threshold_uncertainty_score":0.03616619,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3133509869","doi":"10.1056/nejmoa1911149","title":"Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":841,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"Novartis Institutes for BioMedical Research; Astex Pharmaceuticals; Novartis","keywords":"Fulvestrant; Oncology; Medicine; Internal medicine; Interim analysis; Cancer; Breast cancer; Human Epidermal Growth Factor Receptor 2; Hormone receptor; Metastatic breast cancer; Clinical trial; Estrogen receptor","authors":[{"name":"Dennis J. Slamon","is_ca":false},{"name":"Patrick Neven","is_ca":false},{"name":"Stephen Chia","is_ca":true},{"name":"Peter A. Fasching","is_ca":false},{"name":"Michelino De Laurentiis","is_ca":false},{"name":"Seock‐Ah Im","is_ca":false},{"name":"Katarína Petráková","is_ca":false},{"name":"Giulia Bianchi","is_ca":false},{"name":"Francisco J. Esteva","is_ca":false},{"name":"Miguel Martín","is_ca":false},{"name":"Arnd Nusch","is_ca":false},{"name":"Gabe S. Sonke","is_ca":false},{"name":"Luis de la Cruz‐Merino","is_ca":false},{"name":"J. Thaddeus Beck","is_ca":false},{"name":"Xavier Pivot","is_ca":false},{"name":"Manu Sondhi","is_ca":false},{"name":"Yingbo Wang","is_ca":false},{"name":"Arunava Chakravartty","is_ca":false},{"name":"Karen Rodriguez-Lorenc","is_ca":false},{"name":"Tetiana Taran","is_ca":false},{"name":"Guy Jérusalem","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01125536094792389,"gpt":0.2819309661319838,"spread":0.2706756051840599,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002016509,0.0004663757,0.0009815978,0.0003160218,0.0001074732,0.0003411692,0.0002916363,0.000314533,0.001599191],"category_scores_gemma":[0.001045454,0.00008462976,0.001290312,0.0002554279,0.0002540481,0.0002641142,0.0003362611,0.0007671487,0.0001718443],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004513633,"about_ca_system_score_gemma":0.0006198118,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002512917,"about_ca_topic_score_gemma":0.0006719169,"domain_scores_codex":[0.9995776,0.0002112611,0.0000240596,0.00005530466,0.00006200193,0.00006980638],"domain_scores_gemma":[0.9995781,0.0001316335,0.0001274356,0.0000387958,0.00002545555,0.00009864355],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5498958,0.004977269,0.03258139,0.001265657,0.00309894,0.0002265407,0.0001411531,0.008365161,0.02346944,0.0003751449,0.003428764,0.3721747],"study_design_scores_gemma":[0.1813729,0.5445829,0.2338703,0.000388973,0.006002312,0.001041148,0.00007881624,0.004341404,0.01188462,0.001610814,0.01477291,0.00005282215],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9837903,0.01193381,0.00095151,0.0004416962,0.0001175825,0.0002794385,0.0005618923,0.00006700816,0.001856563],"genre_scores_gemma":[0.994753,0.002805769,0.0005681951,0.0002518721,0.00009216961,0.0002813188,0.0007857335,0.000007269647,0.0004548273],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002016509,"threshold_uncertainty_score":0.01066446,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2558360748","doi":"10.1016/s0140-6736(16)32389-3","title":"Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":602,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Jewish General Hospital","funders":"AstraZeneca","keywords":"Anastrozole; Fulvestrant; Medicine; Internal medicine; Hazard ratio; Breast cancer; Oncology; Clinical endpoint; Population; Placebo; Aromatase inhibitor; Metastatic breast cancer; Cancer; Gynecology; Randomized controlled trial; Estrogen receptor; Tamoxifen; Confidence interval; Pathology","authors":[{"name":"J.F.R. Robertson","is_ca":false},{"name":"Ekaterina Trishkina","is_ca":false},{"name":"Mikhail Dvorkin","is_ca":false},{"name":"Lawrence Panasci","is_ca":true},{"name":"Alexey Manikhas","is_ca":false},{"name":"Yaroslav Shparyk","is_ca":false},{"name":"Servando Cardona‐Huerta","is_ca":false},{"name":"Kwok‐Leung Cheung","is_ca":false},{"name":"Manuel Jesus Philco-Salas","is_ca":false},{"name":"Manuel Ruíz‐Borrego","is_ca":false},{"name":"Zhimin Shao","is_ca":false},{"name":"Shinzaburo Noguchi","is_ca":false},{"name":"Jacqui Rowbottom","is_ca":false},{"name":"Mary Stuart","is_ca":false},{"name":"Lynda Grinsted","is_ca":false},{"name":"Mehdi Fazal","is_ca":false},{"name":"Matthew J. Ellis","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06965433626529506,"gpt":0.3886010275041646,"spread":0.3189466912388696,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001386245,0.001966497,0.002098913,0.0004867091,0.0003923394,0.0009192229,0.0008842617,0.001800569,0.009488796],"category_scores_gemma":[0.001581619,0.000571034,0.001751074,0.0004311931,0.001167677,0.001313491,0.0004105546,0.002529773,0.001411657],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008153904,"about_ca_system_score_gemma":0.0008269287,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001441307,"about_ca_topic_score_gemma":0.002780876,"domain_scores_codex":[0.9995962,0.0002008693,0.00002101667,0.00007560277,0.00002877027,0.00007769204],"domain_scores_gemma":[0.9994598,0.0001856825,0.000114477,0.00005131968,0.0000296441,0.0001590603],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9828486,0.001521017,0.000190517,0.0004095311,0.0005102694,0.00002195094,0.00002941897,0.0002576275,0.001424323,0.0001301211,0.001029924,0.01162659],"study_design_scores_gemma":[0.9804721,0.01773164,0.0005497343,0.00002172657,0.0002285933,0.00001979485,0.00001325198,0.0001897684,0.0001363648,0.0001376232,0.000489453,0.000009890627],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9716249,0.01159408,0.001261506,0.002092879,0.001229114,0.004220559,0.002496048,0.0004127964,0.005068058],"genre_scores_gemma":[0.9764445,0.004957396,0.001854399,0.002301491,0.0005365525,0.004332665,0.001882841,0.00005420129,0.007635878],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009488796,"threshold_uncertainty_score":0.03174317,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2151082560","doi":"10.1093/annonc/mdu456","title":"Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":568,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hôpital du Saint-Sacrement; Sunnybrook Health Science Centre; University of Toronto","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Exemestane; Human Epidermal Growth Factor Receptor 2; Everolimus; Oncology; Internal medicine; Hormone receptor; Breast cancer; Cancer research; Cancer; Aromatase","authors":[{"name":"Martine Piccart","is_ca":false},{"name":"Gabriel N. Hortobágyi","is_ca":false},{"name":"Mario Campone","is_ca":false},{"name":"Kathleen I. Pritchard","is_ca":true},{"name":"Fabienne Lebrun","is_ca":false},{"name":"Yoshiaki Ito","is_ca":false},{"name":"Shinzaburo Noguchi","is_ca":false},{"name":"Alejandra Perez","is_ca":false},{"name":"Hope S. Rugo","is_ca":false},{"name":"Ines Deleu","is_ca":false},{"name":"Howard A. Burris","is_ca":false},{"name":"Louise Provencher","is_ca":true},{"name":"Patrick Neven","is_ca":false},{"name":"Michael Gnant","is_ca":false},{"name":"Mikhail Shtivelband","is_ca":false},{"name":"Cheng-Han Wu","is_ca":false},{"name":"Jiaxin Fan","is_ca":false},{"name":"Wentao Feng","is_ca":false},{"name":"T Taran","is_ca":false},{"name":"José Baselga","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0499435101726918,"gpt":0.3632289122475997,"spread":0.313285402074908,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001114909,0.0008199129,0.00125456,0.0005114802,0.0003321375,0.0008786019,0.0004566893,0.0004892861,0.002278634],"category_scores_gemma":[0.0005893857,0.0002462444,0.002084616,0.0004797841,0.0004807191,0.0006422707,0.0003968439,0.001623077,0.0004633077],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009757594,"about_ca_system_score_gemma":0.0008497904,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002263409,"about_ca_topic_score_gemma":0.006393326,"domain_scores_codex":[0.9996392,0.0001239425,0.00003023334,0.00007561389,0.0000553781,0.00007554758],"domain_scores_gemma":[0.9995957,0.00007818457,0.00009187231,0.00005290566,0.00002463784,0.0001566424],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6833244,0.02468771,0.03184944,0.001230131,0.006510664,0.000339854,0.0003838049,0.003051577,0.0220637,0.0003246206,0.00338353,0.2228505],"study_design_scores_gemma":[0.2550368,0.4378955,0.2595462,0.0004601637,0.01441247,0.001450017,0.0004152117,0.001826901,0.008699222,0.0005219509,0.01960477,0.0001306745],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9851599,0.009374671,0.0001340785,0.0002776054,0.00009845876,0.000136065,0.001514577,0.00002554212,0.00327916],"genre_scores_gemma":[0.973679,0.01272624,0.0007385812,0.0009251611,0.0003138,0.0001860284,0.006082972,0.00004396963,0.005304283],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002278634,"threshold_uncertainty_score":0.007622778,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2908699784","doi":"10.1007/s10549-018-05125-4","title":"Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up","year":2019,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":442,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; University of Alberta","funders":"Pfizer","keywords":"Palbociclib; Letrozole; Medicine; Breast cancer; Oncology; Internal medicine; Placebo; Metastatic breast cancer; Hazard ratio; Estrogen receptor; Population; Cancer; Gynecology; Tamoxifen; Confidence interval; Pathology","authors":[{"name":"Hope S. Rugo","is_ca":false},{"name":"Richard S. Finn","is_ca":false},{"name":"Véronique Dièras","is_ca":false},{"name":"Johannes Ettl","is_ca":false},{"name":"Oleg Lipatov","is_ca":false},{"name":"Anil A. Joy","is_ca":true},{"name":"Nadia Harbeck","is_ca":false},{"name":"Aurelio Castrellon","is_ca":false},{"name":"Shrividya Iyer","is_ca":false},{"name":"Dongrui R. Lu","is_ca":false},{"name":"A. Mori","is_ca":false},{"name":"Eric Gauthier","is_ca":false},{"name":"Cynthia Huang Bartlett","is_ca":false},{"name":"Karen A. Gelmon","is_ca":true},{"name":"Dennis J. Slamon","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03527075155297768,"gpt":0.3551255762284284,"spread":0.3198548246754507,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001221369,0.0004765534,0.001308603,0.0003654525,0.000202792,0.0004160695,0.000481931,0.0003632556,0.001788722],"category_scores_gemma":[0.0007147255,0.0002018383,0.0009134794,0.0004044871,0.0002691733,0.0003933063,0.0002412919,0.0009909832,0.0003001369],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006856638,"about_ca_system_score_gemma":0.0008955521,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006850861,"about_ca_topic_score_gemma":0.003038975,"domain_scores_codex":[0.9996709,0.0001635446,0.00002060344,0.00004837938,0.00005693828,0.00003961804],"domain_scores_gemma":[0.9996983,0.00007579641,0.0000800675,0.00003166917,0.00002124392,0.0000929384],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7474058,0.0107898,0.01735807,0.001056236,0.002350348,0.0002554793,0.0001119572,0.002145939,0.01828446,0.0001114201,0.001600757,0.1985297],"study_design_scores_gemma":[0.5469165,0.3427089,0.09221502,0.0001636563,0.002716458,0.0008010418,0.00006931113,0.002547687,0.006537898,0.0002730345,0.00501365,0.00003690528],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.991576,0.005715855,0.0002632643,0.0001666722,0.00004744855,0.0006034967,0.0004234433,0.00004516261,0.00115879],"genre_scores_gemma":[0.9957513,0.001838222,0.0004941089,0.0001773139,0.00006079443,0.000457048,0.0006021333,0.000005668142,0.0006134352],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001788722,"threshold_uncertainty_score":0.006459296,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3024684302","doi":"10.1158/2159-8290.cd-19-1390","title":"The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer","year":2020,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":433,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Alberta Cancer Foundation; Jewish General Hospital; Institute of Cancer Research","funders":"National Cancer Institute; Susan G. Komen; American Association for Cancer Research; U.S. Department of Defense","keywords":"Cancer research; Breast cancer; KRAS; AKT1; Cancer; Metastatic breast cancer; Cyclin-dependent kinase 4; CHEK1; Kinase; Biology; Estrogen receptor; Cyclin-dependent kinase 6; Medicine; Internal medicine; Cell cycle; Cyclin-dependent kinase; Cell cycle checkpoint; Signal transduction; PI3K/AKT/mTOR pathway; Cyclin-dependent kinase 2; Genetics; Colorectal cancer","authors":[{"name":"Seth A. Wander","is_ca":false},{"name":"Ofir Cohen","is_ca":false},{"name":"Xueqian Gong","is_ca":false},{"name":"Gabriela N. Johnson","is_ca":false},{"name":"Jorge E. Buendia-Buendia","is_ca":false},{"name":"Maxwell R. Lloyd","is_ca":false},{"name":"Dewey Kim","is_ca":false},{"name":"Flora Luo","is_ca":false},{"name":"Pingping Mao","is_ca":false},{"name":"Karla Helvie","is_ca":false},{"name":"Kailey J. Kowalski","is_ca":false},{"name":"Utthara Nayar","is_ca":false},{"name":"Adrienne G. Waks","is_ca":false},{"name":"Stephen H. Parsons","is_ca":false},{"name":"Ricardo Martínez","is_ca":false},{"name":"Lacey M. Litchfield","is_ca":false},{"name":"Xiang S. Ye","is_ca":false},{"name":"Chunping Yu","is_ca":false},{"name":"Valerie M. Jansen","is_ca":false},{"name":"John R. Stille","is_ca":false},{"name":"Patricia S. Smith","is_ca":false},{"name":"Gerard J. Oakley","is_ca":false},{"name":"Quincy S. Chu","is_ca":true},{"name":"Gerald Batist","is_ca":true},{"name":"Melissa E. Hughes","is_ca":false},{"name":"Jill D. Kremer","is_ca":false},{"name":"Levi A. Garraway","is_ca":false},{"name":"Eric P. Winer","is_ca":false},{"name":"Sara M. Tolaney","is_ca":false},{"name":"Nancy U. Lin","is_ca":false},{"name":"Sean G. Buchanan","is_ca":false},{"name":"Nikhil Wagle","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.007344171976413173,"gpt":0.2373030143662544,"spread":0.2299588423898413,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001460541,0.0001138784,0.000190223,0.0004705153,0.0001846458,0.0003450622,0.0001283548,0.000261735,0.00203251],"category_scores_gemma":[0.0006923269,0.00009089094,0.0001247644,0.0004560569,0.0001834026,0.0001718135,0.0001861072,0.0002512941,0.0001841027],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001597783,"about_ca_system_score_gemma":0.00008995135,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005692328,"about_ca_topic_score_gemma":0.0007107699,"domain_scores_codex":[0.999853,0.00002744992,0.000010693,0.00005083439,0.0000268472,0.00003114755],"domain_scores_gemma":[0.9997247,0.0000805317,0.0001051929,0.00002063473,0.00002641312,0.00004240017],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0006710091,0.00002967814,0.9720783,0.00001850404,0.00006045097,0.0006878072,0.00008142422,0.0002247031,0.01667661,0.000107919,0.0002696352,0.009093856],"study_design_scores_gemma":[0.00001001701,0.0001320545,0.9951734,0.000004068987,0.00003547986,0.002039597,0.000113171,0.0004902052,0.001308796,0.0001379252,0.000551362,0.000003825607],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9990252,0.0001952906,0.00008355768,0.00006151317,0.000001731517,0.00000309716,0.0002180696,0.000004887586,0.0004065624],"genre_scores_gemma":[0.9997091,0.00004037598,0.00004616503,0.00001633384,0.000003821192,0.000001828518,0.0001155768,0.000001617906,0.00006523756],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00203251,"threshold_uncertainty_score":0.006799459,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4386102828","doi":"10.1016/s0140-6736(23)01245-x","title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":427,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"MacroGenics; Puma Biotechnology; Mylan; Gilead Sciences; Amgen; Pfizer; Samsung; Genentech; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Metastatic breast cancer; Internal medicine; Oncology; Clinical endpoint; Breast cancer; Hazard ratio; Taxane; Cancer; Clinical trial; Confidence interval","authors":[{"name":"Hope S. Rugo","is_ca":false},{"name":"Aditya Bardia","is_ca":false},{"name":"Frederik Marmé","is_ca":false},{"name":"Javier Cortés","is_ca":false},{"name":"Peter Schmid","is_ca":false},{"name":"Delphine Loirat","is_ca":false},{"name":"Olivier Trédan","is_ca":false},{"name":"Eva Ciruelos","is_ca":false},{"name":"Florence Dalenc","is_ca":false},{"name":"P. Gómez Pardo","is_ca":false},{"name":"Komal Jhaveri","is_ca":false},{"name":"Rosemary Delaney","is_ca":false},{"name":"T. Valdez","is_ca":false},{"name":"Hao Wang","is_ca":false},{"name":"Monica Motwani","is_ca":false},{"name":"Oh Kyu Yoon","is_ca":false},{"name":"Wendy Verret","is_ca":false},{"name":"Sara M. Tolaney","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05675231104043848,"gpt":0.3583262430471858,"spread":0.3015739320067473,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003062778,0.001551281,0.001634733,0.0004300499,0.0003435331,0.001071496,0.0009080648,0.001371801,0.003872701],"category_scores_gemma":[0.001493895,0.0004007251,0.001618353,0.0005348333,0.001228543,0.0008489292,0.0005305265,0.002429747,0.0005691707],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001284747,"about_ca_system_score_gemma":0.001370327,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001093079,"about_ca_topic_score_gemma":0.002866457,"domain_scores_codex":[0.999189,0.0005221249,0.0000307639,0.0001013945,0.00005451412,0.000102273],"domain_scores_gemma":[0.9989447,0.000200832,0.0002846257,0.00008550457,0.00006043035,0.0004240324],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9740175,0.006686565,0.001157255,0.0003012412,0.0004091988,0.00004382781,0.00007517354,0.0008276021,0.004448208,0.00008604497,0.0008038576,0.01114351],"study_design_scores_gemma":[0.8749405,0.1207858,0.002547906,0.00001993637,0.000196874,0.00006162505,0.00002110026,0.0003313296,0.0004582464,0.0001012099,0.0005251836,0.00001029404],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948716,0.00141594,0.0001745879,0.0002773885,0.0001252037,0.001601904,0.0005438508,0.000039377,0.0009500538],"genre_scores_gemma":[0.9928612,0.001012452,0.0006116125,0.0005210999,0.0001792884,0.002288861,0.001187151,0.0000171305,0.001321123],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003872701,"threshold_uncertainty_score":0.01619774,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4392977246","doi":"10.1056/nejmoa2305488","title":"Ribociclib plus Endocrine Therapy in Early Breast Cancer","year":2024,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":357,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Letrozole; Breast cancer; Anastrozole; Internal medicine; Goserelin; Oncology; Aromatase inhibitor; Cancer; Interim analysis; Clinical endpoint; Tamoxifen; Gynecology; Randomized controlled trial","authors":[{"name":"Dennis J. Slamon","is_ca":false},{"name":"Oleg Lipatov","is_ca":false},{"name":"Zbigniew Nowecki","is_ca":false},{"name":"Nicholas P. McAndrew","is_ca":false},{"name":"Bożena Kukiełka-Budny","is_ca":false},{"name":"Daniil Stroyakovskiy","is_ca":false},{"name":"Denise A. Yardley","is_ca":false},{"name":"Chiun‐Sheng Huang","is_ca":false},{"name":"Peter A. Fasching","is_ca":false},{"name":"John Crown","is_ca":false},{"name":"Aditya Bardia","is_ca":false},{"name":"Stephen Chia","is_ca":true},{"name":"Seock‐Ah Im","is_ca":false},{"name":"Manuel Ruíz-Borrego","is_ca":false},{"name":"Sherene Loi","is_ca":false},{"name":"Binghe Xu","is_ca":false},{"name":"Sara A. Hurvitz","is_ca":false},{"name":"Carlos H. Barrios","is_ca":false},{"name":"Michael Untch","is_ca":false},{"name":"Rebecca Moroose","is_ca":false},{"name":"F. Visco","is_ca":false},{"name":"Karen Afenjar","is_ca":false},{"name":"Rodrigo Fresco","is_ca":false},{"name":"Irene Severin","is_ca":false},{"name":"Yan Ji","is_ca":false},{"name":"Farhat Ghaznawi","is_ca":false},{"name":"Zheng Li","is_ca":false},{"name":"Juan Pablo Zarate","is_ca":false},{"name":"Arunava Chakravartty","is_ca":false},{"name":"Tetiana Taran","is_ca":false},{"name":"Gabriel N. Hortobágyi","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02150004405986991,"gpt":0.3288692249692114,"spread":0.3073691809093416,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001601076,0.0003999202,0.001042061,0.0003267331,0.0001353755,0.000428616,0.0003896107,0.0004729436,0.00287874],"category_scores_gemma":[0.001182127,0.0001178709,0.0006520424,0.0003959213,0.0003547129,0.0002912767,0.0002565997,0.001266832,0.0003881087],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004448313,"about_ca_system_score_gemma":0.0008641059,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003271034,"about_ca_topic_score_gemma":0.001430388,"domain_scores_codex":[0.9995259,0.0002785395,0.00004438136,0.00004915826,0.00004807573,0.00005406475],"domain_scores_gemma":[0.9994268,0.0002291239,0.0001160371,0.00004011377,0.00003244917,0.0001554582],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7246861,0.01114245,0.003772848,0.002740546,0.001031399,0.0002135568,0.00009388164,0.002097557,0.01335489,0.0004653939,0.002142166,0.2382591],"study_design_scores_gemma":[0.6005184,0.368201,0.01022887,0.0003834208,0.001491099,0.0006628846,0.00003877348,0.001150706,0.004618605,0.0007118689,0.01196841,0.00002604271],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9427202,0.04523921,0.001269328,0.0009401841,0.0003947537,0.002323473,0.0008071925,0.00009741322,0.006208101],"genre_scores_gemma":[0.9839516,0.009402379,0.001885163,0.001036402,0.0002404398,0.001330736,0.0006616688,0.00001510894,0.001476463],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00287874,"threshold_uncertainty_score":0.009630322,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2947470150","doi":"10.1038/s41523-019-0111-0","title":"SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer","year":2019,"lang":"en","type":"article","venue":"npj Breast Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":355,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Ottawa","funders":"National Cancer Institute; National Institutes of Health; Berlin Institute of Health; Deutsche Forschungsgemeinschaft; Breast Cancer Research Foundation","keywords":"Breast cancer; Metastatic breast cancer; Medicine; Internal medicine; Oncology; Cancer; Targeted therapy; Endocrine system; Hormone; Bioinformatics; Cancer research; Biology","authors":[{"name":"Bruno V. Sinn","is_ca":false},{"name":"Chunxiao Fu","is_ca":false},{"name":"Rosanna Lau","is_ca":false},{"name":"Jennifer K. Litton","is_ca":false},{"name":"Tsung‐Heng Tsai","is_ca":false},{"name":"Rashmi K. Murthy","is_ca":false},{"name":"Alda L. Tam","is_ca":false},{"name":"Eleni Andreopoulou","is_ca":false},{"name":"Yun Gong","is_ca":false},{"name":"Ravi Murthy","is_ca":false},{"name":"Rebekah Gould","is_ca":false},{"name":"Ya Zhang","is_ca":false},{"name":"Tari A. King","is_ca":false},{"name":"Agnès Viale","is_ca":false},{"name":"Victor Piana de Andrade","is_ca":false},{"name":"Dilip D. Giri","is_ca":false},{"name":"Roberto Salgado","is_ca":false},{"name":"Ioanna Laı̈os","is_ca":false},{"name":"Christos Sotiriou","is_ca":false},{"name":"Esmeralda Celia Marginean","is_ca":true},{"name":"Danielle Kwiatkowski","is_ca":false},{"name":"Rachel M. Layman","is_ca":false},{"name":"Daniel J. Booser","is_ca":false},{"name":"Christos Hatzis","is_ca":false},{"name":"Vicente Valero","is_ca":false},{"name":"W. Fraser Symmans","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03199847053610999,"gpt":0.3266311783684151,"spread":0.2946327078323051,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00129964,0.0003833641,0.0004319151,0.0006795313,0.0001200097,0.0004726505,0.0002419404,0.0003476267,0.001450133],"category_scores_gemma":[0.002654377,0.0001442629,0.0003858399,0.0003542759,0.0002557808,0.000227033,0.0003074824,0.0005277037,0.0003159636],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002158346,"about_ca_system_score_gemma":0.000142782,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003186949,"about_ca_topic_score_gemma":0.0004348957,"domain_scores_codex":[0.9993857,0.0001865235,0.00004905433,0.0001699876,0.00016159,0.00004716173],"domain_scores_gemma":[0.9984097,0.0007230796,0.0005054588,0.0001138252,0.000126793,0.0001211523],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002164534,0.000106935,0.9077742,0.00006401544,0.0003122568,0.0001450561,0.00004095913,0.003970382,0.06194912,0.0001084146,0.0005177671,0.02284643],"study_design_scores_gemma":[0.00007057837,0.001120721,0.9369379,0.00001395835,0.0002839165,0.001291945,0.00007978144,0.02839121,0.03006823,0.0004648493,0.001242388,0.00003469709],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9928225,0.0004992408,0.004871576,0.00008818007,0.0000124123,0.00002260021,0.001079639,0.00009461315,0.0005092583],"genre_scores_gemma":[0.9959853,0.00006218781,0.00296656,0.00004513869,0.000017641,0.00002061708,0.000657995,0.00001261076,0.0002317484],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001450133,"threshold_uncertainty_score":0.00687319,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3141372695","doi":"10.1016/s1470-2045(21)00034-6","title":"Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":349,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Fulvestrant; Medicine; Aromatase inhibitor; Internal medicine; Oncology; Breast cancer; Cancer; Cohort; Regimen; Clinical endpoint; Clinical trial; Estrogen receptor; Aromatase","authors":[{"name":"Hope S. Rugo","is_ca":false},{"name":"Florence Lerebours","is_ca":false},{"name":"Eva Ciruelos","is_ca":false},{"name":"Pamela Drullinsky","is_ca":false},{"name":"Manuel Ruíz‐Borrego","is_ca":false},{"name":"Patrick Neven","is_ca":false},{"name":"Yeon Hee Park","is_ca":false},{"name":"Aleix Prat","is_ca":false},{"name":"Thomas Bachelot","is_ca":false},{"name":"Dejan Juric","is_ca":false},{"name":"Nicholas C. Turner","is_ca":false},{"name":"Nickolas A. Sophos","is_ca":false},{"name":"Juan Pablo Zarate","is_ca":false},{"name":"Christina Arce","is_ca":false},{"name":"Yu-Ming Shen","is_ca":false},{"name":"Stuart Turner","is_ca":false},{"name":"Hemanth Kanakamedala","is_ca":false},{"name":"Wei‐Chun Hsu","is_ca":false},{"name":"Stephen Chia","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05096464552649327,"gpt":0.3993410276253444,"spread":0.3483763820988511,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002448632,0.001313025,0.002592248,0.0004860409,0.0003679259,0.001304171,0.0006919882,0.001168981,0.00251498],"category_scores_gemma":[0.001665669,0.0004332487,0.002304659,0.0005312184,0.0009815631,0.001261545,0.00031729,0.002229874,0.0006026875],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00111719,"about_ca_system_score_gemma":0.0008150821,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001499154,"about_ca_topic_score_gemma":0.003109957,"domain_scores_codex":[0.999175,0.0004045277,0.00004176815,0.0001270418,0.00006839196,0.0001832059],"domain_scores_gemma":[0.9989355,0.0003546507,0.0002003741,0.0001450156,0.00006511289,0.0002993083],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9341796,0.01058382,0.005436638,0.0005030094,0.002525562,0.0001065499,0.0001267622,0.0007854978,0.007449793,0.0001218328,0.0007600661,0.03742071],"study_design_scores_gemma":[0.6140949,0.3542387,0.02431028,0.00005858281,0.002459098,0.0002134414,0.0001322446,0.0006426694,0.001706933,0.0002440178,0.00185131,0.00004779493],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949609,0.003071714,0.0001913357,0.000171785,0.0001098648,0.0003049906,0.0004878066,0.00002186894,0.000679719],"genre_scores_gemma":[0.9937158,0.002261817,0.000456653,0.0004603232,0.0002093161,0.0003221217,0.001367775,0.00001643003,0.001189843],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002592248,"threshold_uncertainty_score":0.01294976,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3148345241","doi":"10.1200/jco.20.03639","title":"Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":324,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Palbociclib; Oncology; Internal medicine; Lapatinib; Taxane; Breast cancer; Letrozole; Estrogen receptor; Hormone receptor; Aromatase inhibitor; Gynecology; Tamoxifen; Cancer; Trastuzumab; Metastatic breast cancer","authors":[{"name":"Sibylle Loibl","is_ca":false},{"name":"Frederik Marmé","is_ca":false},{"name":"Miguel Martín","is_ca":false},{"name":"Michael Untch","is_ca":false},{"name":"Hervé Bonnefoi","is_ca":false},{"name":"Sung‐Bae Kim","is_ca":false},{"name":"Harry D. Bear","is_ca":false},{"name":"Nicole McCarthy","is_ca":false},{"name":"Mireia Melé","is_ca":false},{"name":"Karen A. Gelmon","is_ca":true},{"name":"José Á. García-Sáenz","is_ca":false},{"name":"Catherine M. Kelly","is_ca":false},{"name":"Toralf Reimer","is_ca":false},{"name":"Masakazu Toi","is_ca":false},{"name":"Hope S. Rugo","is_ca":false},{"name":"Carsten Denkert","is_ca":false},{"name":"Michael Gnant","is_ca":false},{"name":"Andreas Makris","is_ca":false},{"name":"María Koehler","is_ca":false},{"name":"Cynthia Huang-Bartelett","is_ca":false},{"name":"Maria Jose Lechuga Frean","is_ca":false},{"name":"Marco Colleoni","is_ca":false},{"name":"Gustavo Werutsky","is_ca":false},{"name":"Sabine Seiler","is_ca":false},{"name":"Nicole Burchardi","is_ca":false},{"name":"Valentina Nekljudova","is_ca":false},{"name":"Gϋnter von Minckwitz","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08584686499972378,"gpt":0.4566029099254679,"spread":0.3707560449257442,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008269362,0.0007275185,0.001140352,0.0002235911,0.0001727983,0.0007097357,0.0005026222,0.0005356176,0.007812306],"category_scores_gemma":[0.0005728138,0.0001507237,0.0005828456,0.0002703201,0.0003489878,0.0004077643,0.0002349203,0.001680459,0.0007556753],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004897054,"about_ca_system_score_gemma":0.0005455256,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00061987,"about_ca_topic_score_gemma":0.001456927,"domain_scores_codex":[0.9997985,0.00009393355,0.00001041674,0.00003490076,0.00002725285,0.00003502677],"domain_scores_gemma":[0.9997972,0.00004795985,0.00003172363,0.00001225128,0.00001284036,0.00009801066],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6703422,0.006085049,0.004311251,0.003062065,0.001433061,0.0002509339,0.00006535908,0.00194571,0.007927939,0.0009584847,0.01446054,0.2891574],"study_design_scores_gemma":[0.8969511,0.07242636,0.01247753,0.0003757846,0.0007859123,0.0005217472,0.00005090714,0.002052692,0.001846373,0.0007621622,0.01172545,0.00002394155],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8935021,0.06958609,0.001755305,0.001839113,0.0006918959,0.004621175,0.00518819,0.0003228805,0.02249319],"genre_scores_gemma":[0.9640443,0.01450566,0.001099944,0.002047827,0.0003532207,0.002708652,0.004044039,0.00002539439,0.01117099],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007812306,"threshold_uncertainty_score":0.02613473,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3167855488","doi":"10.1016/j.annonc.2021.05.353","title":"Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":278,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"Novartis Institutes for BioMedical Research; Astex Pharmaceuticals","keywords":"Medicine; Fulvestrant; Internal medicine; Hazard ratio; Population; Breast cancer; Placebo; Metastatic breast cancer; Progression-free survival; Clinical endpoint; Oncology; Cancer; Randomized controlled trial; Gastroenterology; Confidence interval; Chemotherapy; Estrogen receptor; Pathology","authors":[{"name":"Dennis J. Slamon","is_ca":false},{"name":"Patrick Neven","is_ca":false},{"name":"Stephen Chia","is_ca":true},{"name":"Guy Jérusalem","is_ca":false},{"name":"Michelino De Laurentiis","is_ca":false},{"name":"Sin‐Hyeog Im","is_ca":false},{"name":"Katarína Petráková","is_ca":false},{"name":"Giulia Bianchi","is_ca":false},{"name":"Miguel Martín","is_ca":false},{"name":"Arnd Nusch","is_ca":false},{"name":"Gabe S. Sonke","is_ca":false},{"name":"Luis de la Cruz‐Merino","is_ca":false},{"name":"J. Thaddeus Beck","is_ca":false},{"name":"Yan Ji","is_ca":false},{"name":"C. Wang","is_ca":false},{"name":"Uday Deore","is_ca":false},{"name":"A. Chakravartty","is_ca":false},{"name":"Juan Pablo Zarate","is_ca":false},{"name":"T Taran","is_ca":false},{"name":"Peter A. Fasching","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04265747474552653,"gpt":0.3792816454752698,"spread":0.3366241707297433,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002414368,0.0007317237,0.001219478,0.0003004479,0.0002454072,0.0008100272,0.0003610858,0.0006208828,0.002266083],"category_scores_gemma":[0.001021932,0.0002260592,0.001526961,0.000305268,0.0003945529,0.0004441459,0.0003376311,0.001180234,0.0003319761],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004699893,"about_ca_system_score_gemma":0.0007945282,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006118026,"about_ca_topic_score_gemma":0.0027734,"domain_scores_codex":[0.9993713,0.0004179842,0.0000297236,0.0000661723,0.00004338196,0.00007145044],"domain_scores_gemma":[0.999616,0.00007839567,0.0001257238,0.0000438793,0.0000281,0.0001077933],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9198014,0.002806896,0.007039446,0.001224316,0.003030878,0.00008481448,0.00006136706,0.0009479456,0.006186002,0.0002301393,0.002996187,0.05559058],"study_design_scores_gemma":[0.8776386,0.08285765,0.02525672,0.0001529127,0.003703913,0.0002332735,0.00005179993,0.0006575242,0.001360312,0.0004464328,0.007611178,0.00002967434],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9660802,0.02186119,0.0009283213,0.001376739,0.0004256415,0.002812108,0.002936442,0.0000857307,0.00349351],"genre_scores_gemma":[0.9843322,0.005118505,0.001152412,0.001275708,0.0003069715,0.002008319,0.003291396,0.00001511321,0.002499412],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002414368,"threshold_uncertainty_score":0.01276851,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4200069316","doi":"10.1158/1078-0432.ccr-21-3032","title":"Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":263,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Ottawa","funders":"National Cancer Institute; Novartis Institutes for BioMedical Research; Astex Pharmaceuticals; Novartis Pharmaceuticals Corporation","keywords":"Overall survival; Randomized controlled trial; Endocrine system; Clinical trial; Breast cancer; Cancer","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.127275101733424,"gpt":0.5170188085085538,"spread":0.3897437067751297,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002096972,0.0009128394,0.001417345,0.0003088082,0.0002385322,0.0008303861,0.0006461309,0.0008835164,0.003663047],"category_scores_gemma":[0.001475928,0.0002659132,0.002054267,0.0002472925,0.0005991708,0.0004661795,0.0003948925,0.002022994,0.0004592507],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006967739,"about_ca_system_score_gemma":0.001071615,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006569505,"about_ca_topic_score_gemma":0.002648399,"domain_scores_codex":[0.9994283,0.0003626099,0.00002636654,0.00007192174,0.00004142868,0.00006934089],"domain_scores_gemma":[0.99924,0.0001721474,0.0002157537,0.00005850646,0.00004318705,0.0002703085],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9694908,0.004373324,0.002651251,0.0003908366,0.001446679,0.00003769629,0.00004237071,0.0005360792,0.002450579,0.00009202951,0.0007520745,0.01773631],"study_design_scores_gemma":[0.8416811,0.1378343,0.01458731,0.00007549804,0.002295001,0.0000994178,0.00004367525,0.001031273,0.0008389566,0.0002004564,0.001289238,0.00002379319],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9933748,0.003149651,0.0001953029,0.0004837952,0.0001647642,0.0006069908,0.0005821026,0.00003680323,0.001405921],"genre_scores_gemma":[0.9950329,0.00103742,0.0003455472,0.0005275256,0.0001697826,0.0007695759,0.0008775164,0.000006467016,0.001233301],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003663047,"threshold_uncertainty_score":0.01225406,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3020482066","doi":"10.1016/s1470-2045(20)30112-1","title":"Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":261,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Eisai; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Trastuzumab; Fulvestrant; Internal medicine; Breast cancer; Oncology; Metastatic breast cancer; Cancer; Chemotherapy; Tamoxifen","authors":[{"name":"Sara M. Tolaney","is_ca":false},{"name":"Andrew Wardley","is_ca":false},{"name":"Stefania Zambelli","is_ca":false},{"name":"John Hilton","is_ca":true},{"name":"Tiffany A. Troso-Sandoval","is_ca":false},{"name":"Francesco Ricci","is_ca":false},{"name":"Seock‐Ah Im","is_ca":false},{"name":"Sung‐Bae Kim","is_ca":false},{"name":"Stephen Johnston","is_ca":false},{"name":"Arlene Chan","is_ca":false},{"name":"Shom Goel","is_ca":false},{"name":"Kristen Catron","is_ca":false},{"name":"Sonya C. Chapman","is_ca":false},{"name":"Gregory L. Price","is_ca":false},{"name":"Zhengyu Yang","is_ca":false},{"name":"M. Corona Gainford","is_ca":false},{"name":"Fabrice André","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05342743091466359,"gpt":0.3829554564653619,"spread":0.3295280255506983,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001307475,0.002001432,0.002575106,0.0005000026,0.0002959456,0.001105097,0.001024521,0.00163503,0.009329692],"category_scores_gemma":[0.001623816,0.0006671583,0.001852372,0.000391959,0.001159372,0.001326589,0.0005296693,0.003188795,0.001422903],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009588978,"about_ca_system_score_gemma":0.0008701767,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001270915,"about_ca_topic_score_gemma":0.003658818,"domain_scores_codex":[0.9995666,0.0002145926,0.00001914741,0.00008394379,0.00003043216,0.00008529547],"domain_scores_gemma":[0.9994572,0.0001721681,0.0001061856,0.00004734139,0.00002858322,0.0001885411],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9797411,0.003917407,0.0002775886,0.0004910358,0.0006479237,0.00002618688,0.00004396004,0.0003440326,0.001598271,0.0001383713,0.0007936193,0.01198049],"study_design_scores_gemma":[0.9608486,0.03676104,0.0008255835,0.0000253073,0.0002997323,0.00002519664,0.00002155431,0.0002713848,0.0001804688,0.0001831144,0.0005461358,0.00001175772],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9844931,0.005674563,0.0005107163,0.00122794,0.0009813972,0.002129334,0.001332192,0.0001567001,0.003494104],"genre_scores_gemma":[0.9799712,0.004053375,0.001270855,0.001419607,0.0006643896,0.002402688,0.001666187,0.00004346464,0.008508307],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009329692,"threshold_uncertainty_score":0.03121096,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3120241209","doi":"10.1016/s1470-2045(20)30642-2","title":"Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":255,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval","funders":"Pfizer","keywords":"Palbociclib; Interim analysis; Medicine; Interim; Adjuvant; Oncology; Breast cancer; Internal medicine; Cancer; Endocrine system; Adjuvant therapy; Gynecology; Clinical trial; Metastatic breast cancer; History; Hormone","authors":[{"name":"Erica L. Mayer","is_ca":false},{"name":"Amylou C. Dueck","is_ca":false},{"name":"Miguel Martín","is_ca":false},{"name":"Gábor Rubovszky","is_ca":false},{"name":"Harold J. Burstein","is_ca":false},{"name":"M. Bellet-Ezquerra","is_ca":false},{"name":"Kathy D. Miller","is_ca":false},{"name":"Nicholas Zdenkowski","is_ca":false},{"name":"Eric P. Winer","is_ca":false},{"name":"Georg Pfeiler","is_ca":false},{"name":"Matthew P. Goetz","is_ca":false},{"name":"Manuel Ruíz‐Borrego","is_ca":false},{"name":"D. Mark Anderson","is_ca":false},{"name":"Zbigniew Nowecki","is_ca":false},{"name":"Sibylle Loibl","is_ca":false},{"name":"Stacy Moulder","is_ca":false},{"name":"Alistair Ring","is_ca":false},{"name":"Florian Fitzal","is_ca":false},{"name":"Tiffany A. Traina","is_ca":false},{"name":"Arlene Chan","is_ca":false},{"name":"Hope S. Rugo","is_ca":false},{"name":"Julie Lemieux","is_ca":true},{"name":"Fernando Henao","is_ca":false},{"name":"Alan P. Lyss","is_ca":false},{"name":"Silvia Antolín","is_ca":false},{"name":"Antonio C. Wolff","is_ca":false},{"name":"Marcus Vetter","is_ca":false},{"name":"Daniel Egle","is_ca":false},{"name":"Patrick G. Morris","is_ca":false},{"name":"Eleftherios P. Mamounas","is_ca":false},{"name":"Miguel Gil‐Gil","is_ca":false},{"name":"Aleix Prat","is_ca":false},{"name":"Hannes Fohler","is_ca":false},{"name":"Otto Metzger","is_ca":false},{"name":"Magdalena Schwarz","is_ca":false},{"name":"Carter DuFrane","is_ca":false},{"name":"Debora Fumagalli","is_ca":false},{"name":"Kathy Puyana Theall","is_ca":false},{"name":"Dongrui R. Lu","is_ca":false},{"name":"Cynthia Huang Bartlett","is_ca":false},{"name":"María Koehler","is_ca":false},{"name":"Christian Fesl","is_ca":false},{"name":"Angela DeMichele","is_ca":false},{"name":"Michael Gnant","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08323415090640111,"gpt":0.4366332390939129,"spread":0.3533990881875118,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006946137,0.002356987,0.00435596,0.000560916,0.0006220289,0.002299901,0.001409381,0.001829889,0.007182674],"category_scores_gemma":[0.004976406,0.0008946105,0.005004029,0.0007412891,0.001369333,0.002169641,0.0009297192,0.005336387,0.001514483],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001336322,"about_ca_system_score_gemma":0.00220274,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001108863,"about_ca_topic_score_gemma":0.003007062,"domain_scores_codex":[0.997189,0.001789761,0.0001214514,0.0002891924,0.000224996,0.0003855421],"domain_scores_gemma":[0.9968052,0.001189527,0.0006941332,0.00045539,0.0001776875,0.0006781837],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9794663,0.001497653,0.0006981238,0.0004387907,0.002378645,0.00003278148,0.00004067694,0.0005810591,0.001027608,0.0001234003,0.001259333,0.01245562],"study_design_scores_gemma":[0.9446517,0.04722232,0.003793865,0.00005476924,0.001742291,0.00006177147,0.00003404506,0.000509636,0.000288589,0.0003997917,0.001209969,0.00003120089],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9593751,0.01528947,0.003115842,0.002042238,0.001289843,0.00570979,0.006918876,0.0004762285,0.005782624],"genre_scores_gemma":[0.971832,0.003721249,0.004503883,0.002370776,0.0005168662,0.006047471,0.006262518,0.0001387614,0.004606488],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007182674,"threshold_uncertainty_score":0.03673512,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2474699717","doi":"10.1634/theoncologist.2016-0097","title":"Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)","year":2016,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":246,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"National Cancer Institute; AstraZeneca; Pfizer","keywords":"Medicine; Palbociclib; Fulvestrant; Neutropenia; Placebo; Metastatic breast cancer; Internal medicine; Adverse effect; Febrile neutropenia; Oncology; Common Terminology Criteria for Adverse Events; Breast cancer; Cancer; Chemotherapy; Estrogen receptor","authors":[{"name":"Sunil Verma","is_ca":true},{"name":"Cynthia Huang Bartlett","is_ca":false},{"name":"Patrick Schnell","is_ca":false},{"name":"Angela DeMichele","is_ca":false},{"name":"Sherene Loi","is_ca":false},{"name":"Jungsil Ro","is_ca":false},{"name":"Marco Colleoni","is_ca":false},{"name":"Hiroji Iwata","is_ca":false},{"name":"Nadia Harbeck","is_ca":false},{"name":"Massimo Cristofanilli","is_ca":false},{"name":"Ke Zhang","is_ca":false},{"name":"Alexandra Thiele","is_ca":false},{"name":"Nicholas C. Turner","is_ca":false},{"name":"Hope S. Rugo","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.009780463777112593,"gpt":0.2961600474988715,"spread":0.2863795837217589,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002269588,0.0007260456,0.001212541,0.0005020935,0.0002437266,0.0005817977,0.0005429382,0.0006464577,0.00328954],"category_scores_gemma":[0.001360831,0.0003102725,0.001353721,0.0006274762,0.0005220337,0.0004232198,0.0002213792,0.001114115,0.0003854533],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006468981,"about_ca_system_score_gemma":0.0009759552,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005549605,"about_ca_topic_score_gemma":0.001742505,"domain_scores_codex":[0.9993436,0.0003801439,0.00005056222,0.00008882802,0.00008180115,0.00005508371],"domain_scores_gemma":[0.9992187,0.0002296449,0.000288547,0.0000647947,0.00005781511,0.0001406036],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8344373,0.01125896,0.01451221,0.001732448,0.004719192,0.0001865188,0.0001208985,0.001787266,0.02226943,0.0001103431,0.001657577,0.1072079],"study_design_scores_gemma":[0.7248825,0.2258497,0.03987913,0.00009667047,0.003029519,0.0003384302,0.00004534434,0.0008058735,0.002414028,0.0001329478,0.002500709,0.00002513209],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9852737,0.008833434,0.0006564335,0.0003164448,0.0000588959,0.002009969,0.001413308,0.00006881243,0.001369063],"genre_scores_gemma":[0.9939831,0.002536621,0.0004926965,0.0003165358,0.0001037519,0.0008791511,0.001253167,0.00001059462,0.0004243071],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00328954,"threshold_uncertainty_score":0.01200283,"prediction_status":"machine_predicted_unvalidated"},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W2902672529","doi":"10.1200/jco.18.01624","title":"Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":235,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre; Centre Hospitalier de l’Université de Montréal; Centre hospitalier de l'Université Laval; Institute of Cancer Research; Jewish General Hospital","funders":"Daiichi Sankyo Europe; Genentech; Astellas Pharma; Eisai; Cancer Research UK; GlaxoSmithKline; Public Health Agency; MacroGenics; National Institute for Health and Care Research; Teva Pharmaceutical Industries; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Genomic Health","keywords":"Letrozole; Palbociclib; Medicine; Breast cancer; Estrogen receptor; Internal medicine; Oncology; Urology; Cancer; Metastatic breast cancer; Tamoxifen","authors":[{"name":"Stephen Johnston","is_ca":false},{"name":"Shannon Puhalla","is_ca":false},{"name":"Duncan Wheatley","is_ca":false},{"name":"Alistair Ring","is_ca":false},{"name":"Peter Barry","is_ca":false},{"name":"Chris Holcombe","is_ca":false},{"name":"Jean Francois Boileau","is_ca":true},{"name":"Louise Provencher","is_ca":true},{"name":"André Robidoux","is_ca":true},{"name":"Mothaffar F. Rimawi","is_ca":false},{"name":"Stuart McIntosh","is_ca":false},{"name":"I. Shalaby","is_ca":false},{"name":"Robert C. Stein","is_ca":false},{"name":"Michael P. Thirlwell","is_ca":true},{"name":"David Dolling","is_ca":true},{"name":"James P. Morden","is_ca":true},{"name":"Claire Snowdon","is_ca":true},{"name":"Sophie Perry","is_ca":true},{"name":"Chester Cornman","is_ca":false},{"name":"Leona Batten","is_ca":true},{"name":"Lisa K. Jeffs","is_ca":true},{"name":"Andrew Dodson","is_ca":false},{"name":"Vera Martins","is_ca":false},{"name":"Arjun Modi","is_ca":false},{"name":"C. Kent Osborne","is_ca":false},{"name":"Katherine L. Pogue–Geile","is_ca":false},{"name":"Maggie C.U. Cheang","is_ca":true},{"name":"Norman Wolmark","is_ca":false},{"name":"Thomas B. Julian","is_ca":false},{"name":"Kate Fisher","is_ca":false},{"name":"Mairead MacKenzie","is_ca":false},{"name":"Maggie Wilcox","is_ca":false},{"name":"Cynthia Huang Bartlett","is_ca":false},{"name":"María Koehler","is_ca":false},{"name":"Mitch Dowsett","is_ca":false},{"name":"Judith M. Bliss","is_ca":true},{"name":"Samuel A. Jacobs","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1484660686979292,"gpt":0.5541645440786152,"spread":0.405698475380686,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001984237,0.002026448,0.002933182,0.0005970351,0.0004623765,0.001400016,0.001316914,0.001820534,0.01144455],"category_scores_gemma":[0.001812961,0.0008500046,0.001347629,0.000487703,0.001240224,0.001355625,0.000564544,0.004201346,0.001692513],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001327173,"about_ca_system_score_gemma":0.002212772,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009272542,"about_ca_topic_score_gemma":0.002874025,"domain_scores_codex":[0.9994554,0.0002935182,0.0000254073,0.000103751,0.00005237377,0.00006951373],"domain_scores_gemma":[0.9990873,0.0001839766,0.0001822735,0.00008087413,0.00005782912,0.0004076553],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9737333,0.00859133,0.0004930145,0.0003238091,0.000481313,0.0000534819,0.00002513675,0.0004745078,0.002729421,0.0001732766,0.001864656,0.01105678],"study_design_scores_gemma":[0.9609198,0.03676687,0.0005578153,0.00001502399,0.0001484852,0.00003675592,0.000009317945,0.0003041406,0.0002260022,0.0001314687,0.0008755441,0.000008789645],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9642517,0.005903699,0.00142117,0.002915974,0.00142048,0.0106705,0.005038365,0.0004066517,0.007971559],"genre_scores_gemma":[0.9499713,0.004054969,0.004121014,0.004422651,0.000888417,0.01282635,0.008493952,0.00009085424,0.01513057],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01144455,"threshold_uncertainty_score":0.03828591,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2974027076","doi":"10.1158/1078-0432.ccr-19-0751","title":"Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer","year":2019,"lang":"en","type":"letter","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":221,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"Pfizer","keywords":"Palbociclib; Letrozole; Breast cancer; Biomarker; Cyclin-dependent kinase 4; Oncology; Metastatic breast cancer; Medicine; Internal medicine; Cancer; Fulvestrant; Cancer research; Biology; Estrogen receptor; Cell cycle; Tamoxifen; Cyclin-dependent kinase 2","authors":[{"name":"Richard S. Finn","is_ca":false},{"name":"Yuan Liu","is_ca":false},{"name":"Zhou Zhu","is_ca":false},{"name":"Miguel Martín","is_ca":false},{"name":"Hope S. Rugo","is_ca":false},{"name":"Véronique Dièras","is_ca":false},{"name":"Seock‐Ah Im","is_ca":false},{"name":"Karen A. Gelmon","is_ca":true},{"name":"Nadia Harbeck","is_ca":false},{"name":"Dongrui R. Lu","is_ca":false},{"name":"Eric Gauthier","is_ca":false},{"name":"Cynthia Huang Bartlett","is_ca":false},{"name":"Dennis J. Slamon","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.264754332948068,"gpt":0.543597462485185,"spread":0.278843129537117,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005279741,0.0002680478,0.0004037218,0.0003833276,0.0001248555,0.0002743254,0.0002282302,0.0003469966,0.001166233],"category_scores_gemma":[0.001237182,0.0001236505,0.000218185,0.0004050786,0.0001325312,0.000173078,0.0001378513,0.0003477734,0.0002208176],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003003846,"about_ca_system_score_gemma":0.0002867575,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006574296,"about_ca_topic_score_gemma":0.0009699076,"domain_scores_codex":[0.9997883,0.00007689335,0.00001674377,0.0000485014,0.00004711917,0.00002253787],"domain_scores_gemma":[0.999605,0.0001170785,0.0001404797,0.00002160783,0.00005882485,0.00005702022],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02664652,0.0006126269,0.8889964,0.0002163585,0.0003858371,0.0003203011,0.00008305462,0.0006761195,0.03298659,0.00006073434,0.0007782392,0.0482373],"study_design_scores_gemma":[0.0004509962,0.007788442,0.9764574,0.0000166013,0.0002495607,0.0009877621,0.00009532811,0.001268157,0.01073844,0.0001088047,0.001825124,0.00001333027],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9953839,0.002518111,0.0002970324,0.0001355653,0.00001691461,0.00006636733,0.0007086251,0.00002304227,0.0008504806],"genre_scores_gemma":[0.9983557,0.0002708506,0.0003564681,0.00009009521,0.00001438262,0.00004591224,0.0005199255,0.000002118028,0.0003445102],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001166233,"threshold_uncertainty_score":0.003901422,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4396732203","doi":"10.1016/j.annonc.2024.04.013","title":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":206,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Regional Municipality of Durham","funders":"Sanofi Genzyme; Gilead Sciences; Sanofi; Pfizer; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company","keywords":"Medicine; Nonsteroidal; Aromatase inhibitor; Aromatase; Oncology; Internal medicine; Breast cancer; Cancer","authors":[{"name":"M.P. Goetz","is_ca":false},{"name":"M. Toi","is_ca":false},{"name":"Jens Huober","is_ca":false},{"name":"J. Sohn","is_ca":false},{"name":"Olivier Trédan","is_ca":false},{"name":"I.H. Park","is_ca":false},{"name":"Mario Campone","is_ca":false},{"name":"Shyr‐Chyr Chen","is_ca":false},{"name":"Luis Manual Manso","is_ca":false},{"name":"Shani Paluch–Shimon","is_ca":false},{"name":"Orit Freedman","is_ca":true},{"name":"Joyce O’Shaughnessy","is_ca":false},{"name":"Xavier Pivot","is_ca":false},{"name":"S.M. Tolaney","is_ca":false},{"name":"Sara A. Hurvitz","is_ca":false},{"name":"Antonio Llombart‐Cussac","is_ca":false},{"name":"Valérie André","is_ca":false},{"name":"Abhijoy Saha","is_ca":false},{"name":"Guido Van Hal","is_ca":false},{"name":"Ashwin Shahir","is_ca":false},{"name":"Hiroaki Iwata","is_ca":false},{"name":"S. Johnston","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1035576446243398,"gpt":0.4507032766043178,"spread":0.3471456319799779,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001323866,0.0006741423,0.001332365,0.0003855853,0.0003237984,0.0005880077,0.0004837838,0.0005462742,0.002094601],"category_scores_gemma":[0.0006241213,0.0002536671,0.001719207,0.0002385924,0.000464741,0.0003719244,0.0003295546,0.001260161,0.0002946558],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001031151,"about_ca_system_score_gemma":0.001269031,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002081224,"about_ca_topic_score_gemma":0.01011051,"domain_scores_codex":[0.99967,0.0001329867,0.00002254042,0.00003616616,0.00005747578,0.00008089784],"domain_scores_gemma":[0.9995247,0.00006329078,0.0001170427,0.00006036623,0.00003575584,0.0001989425],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.791838,0.01863478,0.00822526,0.0009786629,0.002586366,0.0001739159,0.0001737125,0.0016562,0.03247067,0.0002320253,0.002624074,0.1404064],"study_design_scores_gemma":[0.2724949,0.5981509,0.09896842,0.000151425,0.003757368,0.0005457963,0.0001097449,0.001309368,0.0143407,0.0003690106,0.009736944,0.00006541955],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9913028,0.005300864,0.0002707277,0.0002607728,0.00005923094,0.0004060011,0.0007269633,0.00004298036,0.001629589],"genre_scores_gemma":[0.9921577,0.0020264,0.0005700212,0.00049539,0.0001010896,0.0003312545,0.00140781,0.00001524287,0.002895098],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002094601,"threshold_uncertainty_score":0.007481515,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2887054120","doi":"10.1080/15384101.2018.1502567","title":"Targeting the cell cycle in breast cancer: towards the next phase","year":2018,"lang":"en","type":"review","venue":"Cell Cycle","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":201,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Canadian Institutes of Health Research; Campbell Family Institute for Breast Cancer Research","keywords":"Cell cycle; Biology; Cancer; Breast cancer; Cancer research; Cancer cell; Cell growth; Bioinformatics; Genetics","authors":[{"name":"Kelsie L. Thu","is_ca":true},{"name":"Isabel Soria‐Bretones","is_ca":true},{"name":"TW Mak","is_ca":true},{"name":"DW Cescon","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04549567917826845,"gpt":0.3511356198814667,"spread":0.3056399407031983,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004645732,0.00063613,0.0008105785,0.001721157,0.0003395856,0.0008425781,0.0006489584,0.001001185,0.00367936],"category_scores_gemma":[0.0004734405,0.0002260489,0.000332886,0.001549643,0.0004924444,0.001662231,0.0006746526,0.00226298,0.002557348],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007136152,"about_ca_system_score_gemma":0.0009947679,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000968308,"about_ca_topic_score_gemma":0.00205475,"domain_scores_codex":[0.9998708,0.00002215311,0.00001530831,0.00002116648,0.00005395718,0.00001659311],"domain_scores_gemma":[0.9998062,0.00007576874,0.00002412193,0.00000756174,0.00006336435,0.00002298411],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00006512052,0.00007224584,0.000132891,0.01245039,0.00003321631,0.0001620903,0.00008921145,0.0003165277,0.003000838,0.008283627,0.04836571,0.9270281],"study_design_scores_gemma":[0.000006488149,0.00005273397,0.0002358541,0.001269062,0.0000218418,0.0005724331,0.00003645648,0.00004776847,0.0003187854,0.001610234,0.9958217,0.000006630397],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001073624,0.9974958,0.00015705,0.0005437192,0.0003200487,0.000004769167,0.00001403645,0.000009023821,0.001348181],"genre_scores_gemma":[0.0005553411,0.9978003,0.0002328993,0.0003238384,0.0001990006,0.000004998225,0.00002077799,0.000002124106,0.0008607692],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.00367936,"threshold_uncertainty_score":0.01230872,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2154488022","doi":"10.1158/1078-0432.ccr-10-1869","title":"Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study","year":2011,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":181,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hôpital du Saint-Sacrement","funders":"National Cancer Institute","keywords":"Gefitinib; Tamoxifen; Medicine; Internal medicine; Breast cancer; Placebo; Oncology; Metastatic breast cancer; Cancer; Epidermal growth factor receptor; Pathology","authors":[{"name":"C. Kent Osborne","is_ca":true},{"name":"Patrick Neven","is_ca":true},{"name":"Luc Dirix","is_ca":true},{"name":"John R. Mackey","is_ca":true},{"name":"Jean Robert","is_ca":true},{"name":"Craig Underhill","is_ca":true},{"name":"Rachel Schiff","is_ca":true},{"name":"Carolina Gutiérrez","is_ca":true},{"name":"Ilenia Migliaccio","is_ca":true},{"name":"Valsamo Anagnostou","is_ca":true},{"name":"David L. Rimm","is_ca":true},{"name":"Patrick Magill","is_ca":true},{"name":"Mark Sellers","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1388367152218822,"gpt":0.4788527990782955,"spread":0.3400160838564134,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002533747,0.002198459,0.004529623,0.0006802275,0.0004751457,0.001125691,0.0009334534,0.002165431,0.006928897],"category_scores_gemma":[0.002295353,0.0008693666,0.002484891,0.0005607241,0.001225383,0.001323126,0.0004384377,0.002458655,0.001143547],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008859914,"about_ca_system_score_gemma":0.001192696,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006491121,"about_ca_topic_score_gemma":0.001716249,"domain_scores_codex":[0.9989215,0.0006670812,0.00006388464,0.0001592276,0.00006561428,0.0001227556],"domain_scores_gemma":[0.9989088,0.000339677,0.0002802751,0.00009609378,0.00007348321,0.0003016903],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9782026,0.007292854,0.0004529713,0.0005485288,0.0008253509,0.00002815458,0.00002824422,0.0002244012,0.001347393,0.00004322801,0.0003740315,0.01063222],"study_design_scores_gemma":[0.941048,0.05723578,0.0007906979,0.00001980874,0.0002881936,0.0000193272,0.000009055454,0.0001607399,0.0001060341,0.0000501817,0.0002649672,0.000007229807],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9793555,0.009312292,0.0007606397,0.0008850692,0.000850325,0.00601187,0.001028614,0.0001373201,0.001658413],"genre_scores_gemma":[0.9806958,0.005235851,0.00125587,0.001193766,0.0009462307,0.007398868,0.001037864,0.00002539909,0.002210338],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006928897,"threshold_uncertainty_score":0.02317947,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2313479654","doi":"10.1093/annonc/mdw139","title":"Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":178,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre","funders":"Pfizer","keywords":"Fulvestrant; Palbociclib; Medicine; Placebo; Internal medicine; Quality of life (healthcare); Breast cancer; Metastatic breast cancer; Oncology; Cancer; Confidence interval; Anastrozole; Gynecology; Estrogen receptor; Tamoxifen","authors":[{"name":"Nadia Harbeck","is_ca":false},{"name":"Shrividya Iyer","is_ca":false},{"name":"Nicholas C. Turner","is_ca":false},{"name":"Massimo Cristofanilli","is_ca":false},{"name":"Jungsil Ro","is_ca":false},{"name":"Fabrice André","is_ca":false},{"name":"Sherene Loi","is_ca":false},{"name":"S. Verma","is_ca":true},{"name":"Hiroji Iwata","is_ca":false},{"name":"Helen Bhattacharyya","is_ca":false},{"name":"Kathy Puyana Theall","is_ca":false},{"name":"Cynthia Huang Bartlett","is_ca":false},{"name":"Sibylle Loibl","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08696416881545778,"gpt":0.3862310724140349,"spread":0.2992669035985772,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001935764,0.0006629846,0.0009290233,0.0002555002,0.0002080969,0.00069743,0.0005820367,0.0006583676,0.002326631],"category_scores_gemma":[0.00105185,0.000140155,0.001601401,0.0004209996,0.0003837309,0.0003938548,0.0003889418,0.001537557,0.000237469],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005753263,"about_ca_system_score_gemma":0.000601354,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007562829,"about_ca_topic_score_gemma":0.001502122,"domain_scores_codex":[0.999493,0.0003074682,0.00003043784,0.00005094512,0.00006160063,0.00005658655],"domain_scores_gemma":[0.9994591,0.0001287997,0.000203505,0.00002978938,0.00003168188,0.0001471959],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8936217,0.00565875,0.02368636,0.001882797,0.005469728,0.0001300073,0.00009853752,0.002568103,0.00369097,0.0001481711,0.003932198,0.05911267],"study_design_scores_gemma":[0.7010803,0.1378274,0.1457133,0.0003844427,0.005096798,0.0003965476,0.0001199509,0.002798019,0.001513022,0.0004572686,0.004560463,0.00005255567],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9856201,0.01014912,0.0002112472,0.0004503669,0.0001004889,0.0005663537,0.001541369,0.00002977321,0.001331145],"genre_scores_gemma":[0.9926126,0.00262368,0.0002582697,0.0004652744,0.000143364,0.001123745,0.002215048,0.000007179196,0.0005508692],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002326631,"threshold_uncertainty_score":0.01023746,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2719623628","doi":"10.1634/theoncologist.2017-0072","title":"Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"Cancer Research UK; AstraZeneca; American Society of Clinical Oncology; Pfizer","keywords":"Palbociclib; Fulvestrant; Medicine; Goserelin; Anastrozole; Internal medicine; Oncology; Breast cancer; Adverse effect; Neutropenia; Placebo; Letrozole; Gynecology; Cancer; Metastatic breast cancer; Chemotherapy; Tamoxifen","authors":[{"name":"Sibylle Loibl","is_ca":false},{"name":"Nicholas C. Turner","is_ca":false},{"name":"Jungsil Ro","is_ca":false},{"name":"Massimo Cristofanilli","is_ca":false},{"name":"Hiroji Iwata","is_ca":false},{"name":"Seock‐Ah Im","is_ca":false},{"name":"Norikazu Masuda","is_ca":false},{"name":"Sherene Loi","is_ca":false},{"name":"Fabrice André","is_ca":false},{"name":"Nadia Harbeck","is_ca":false},{"name":"Sunil Verma","is_ca":true},{"name":"Elizabeth Folkerd","is_ca":false},{"name":"Kathy Puyana Theall","is_ca":false},{"name":"Justin Hoffman","is_ca":false},{"name":"Ke Zhang","is_ca":false},{"name":"Cynthia Huang Bartlett","is_ca":false},{"name":"Mitch Dowsett","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02206593019534308,"gpt":0.3371386426214998,"spread":0.3150727124261567,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001500879,0.0005833021,0.0009143275,0.0003591115,0.0001834866,0.0007090748,0.0004869152,0.0005282721,0.003638394],"category_scores_gemma":[0.001181295,0.0001801188,0.00141313,0.0004042812,0.0003789963,0.0003849712,0.0003093902,0.001438933,0.0005444766],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007810784,"about_ca_system_score_gemma":0.001093887,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001249122,"about_ca_topic_score_gemma":0.003446594,"domain_scores_codex":[0.9996303,0.0001826142,0.00002385829,0.00005328616,0.00005781659,0.00005215385],"domain_scores_gemma":[0.999385,0.0001804093,0.0001448466,0.00005051592,0.00006566394,0.0001735613],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6127627,0.01629139,0.05150937,0.001689879,0.003912049,0.0005364181,0.0002330746,0.00132454,0.02213828,0.0002142841,0.002979556,0.2864084],"study_design_scores_gemma":[0.2929473,0.4783129,0.1876821,0.0003193922,0.006355416,0.002201917,0.0002026485,0.002147157,0.01319115,0.0004350055,0.01613533,0.00006965712],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9854873,0.009367217,0.0002900179,0.0006994564,0.00006210779,0.0006255565,0.0009611484,0.00004902487,0.002458161],"genre_scores_gemma":[0.994689,0.002234647,0.000381715,0.0004485396,0.00008525405,0.0003089879,0.00106968,0.0000108002,0.0007714904],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003638394,"threshold_uncertainty_score":0.01217163,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3035496509","doi":"10.1158/1078-0432.ccr-20-0224","title":"<i>ESR1</i> Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"National Institute for Health and Care Research; Cancer Research UK; AstraZeneca","keywords":"Fulvestrant; Exemestane; Oncology; Breast cancer; Medicine; Internal medicine; Hormone receptor; Estrogen receptor; Oestrogen receptor; Cancer; Aromatase","authors":[{"name":"Nicholas C. Turner","is_ca":false},{"name":"Claire Swift","is_ca":false},{"name":"Lucy Kilburn","is_ca":false},{"name":"Charlotte Fribbens","is_ca":false},{"name":"Matthew Beaney","is_ca":false},{"name":"Isaac García-Murillas","is_ca":false},{"name":"Aman U. Budzar","is_ca":false},{"name":"J.F.R. Robertson","is_ca":false},{"name":"William J. Gradishar","is_ca":false},{"name":"Martine Piccart","is_ca":false},{"name":"Gaia Schiavon","is_ca":false},{"name":"Judith M. Bliss","is_ca":false},{"name":"Mitch Dowsett","is_ca":false},{"name":"Stephen Johnston","is_ca":false},{"name":"Stephen Chia","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2207194958004969,"gpt":0.5247294331244319,"spread":0.304009937323935,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007958407,0.0009090053,0.002530947,0.0004996534,0.000195325,0.0009514227,0.0004996291,0.0007131596,0.001254131],"category_scores_gemma":[0.004525623,0.0003333878,0.004142479,0.0004347583,0.0004559231,0.0006389719,0.0004400767,0.001469626,0.0001180381],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005680672,"about_ca_system_score_gemma":0.0006726771,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004306757,"about_ca_topic_score_gemma":0.001251982,"domain_scores_codex":[0.9968897,0.002409311,0.0001586684,0.0001988694,0.000209189,0.0001343853],"domain_scores_gemma":[0.9943249,0.00345182,0.001120785,0.0003024739,0.0002346313,0.000565559],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.8704343,0.002275531,0.06680716,0.0006328363,0.01845845,0.00009233702,0.00009031105,0.001910761,0.006572322,0.0001061792,0.0009094583,0.03171037],"study_design_scores_gemma":[0.3748518,0.2141259,0.3335664,0.0002877676,0.05434021,0.0006205747,0.0002537855,0.009005491,0.008854928,0.0005609423,0.003421508,0.0001107629],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9942058,0.004362107,0.0002720127,0.0002271293,0.00005474029,0.000143078,0.0003484712,0.00001169473,0.0003750165],"genre_scores_gemma":[0.9976877,0.0007226686,0.0003470462,0.0001578999,0.0001189444,0.0001255739,0.0006011317,0.000005241961,0.0002338237],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007958407,"threshold_uncertainty_score":0.04208863,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2791840917","doi":"10.1093/annonc/mdy012","title":"Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":155,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"Pfizer","keywords":"Letrozole; Medicine; Palbociclib; Quality of life (healthcare); Breast cancer; Internal medicine; Metastatic breast cancer; Oncology; Placebo; Gynecology; Cancer; Tamoxifen","authors":[{"name":"Hope S. Rugo","is_ca":false},{"name":"Véronique Dièras","is_ca":false},{"name":"Karen A. Gelmon","is_ca":true},{"name":"Richard S. Finn","is_ca":false},{"name":"Dennis J. Slamon","is_ca":false},{"name":"Miguel Martín","is_ca":false},{"name":"Patrick Neven","is_ca":false},{"name":"Yaroslav Shparyk","is_ca":false},{"name":"A. Mori","is_ca":false},{"name":"Dongrui R. Lu","is_ca":false},{"name":"Helen Bhattacharyya","is_ca":false},{"name":"Cynthia Huang Bartlett","is_ca":false},{"name":"Shrividya Iyer","is_ca":false},{"name":"Stephen Johnston","is_ca":false},{"name":"Johannes Ettl","is_ca":false},{"name":"Nadia Harbeck","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2086520558681569,"gpt":0.4783877348419532,"spread":0.2697356789737964,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012351,0.001078175,0.001721194,0.0002767559,0.0001890772,0.0008256303,0.000642972,0.0008430748,0.00354598],"category_scores_gemma":[0.001726855,0.0002430472,0.002204245,0.0003565222,0.0004847793,0.0008612887,0.000410408,0.002668137,0.0005957843],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007354603,"about_ca_system_score_gemma":0.0006421703,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009254382,"about_ca_topic_score_gemma":0.0026366,"domain_scores_codex":[0.9995153,0.0002469764,0.00002376417,0.00007915733,0.0000549645,0.00007994436],"domain_scores_gemma":[0.9994488,0.0002117512,0.0001470928,0.0000461077,0.0000308283,0.0001152451],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9070733,0.002629048,0.006372395,0.001301993,0.007039655,0.0001295402,0.00005758843,0.001874762,0.00290396,0.0002676435,0.003912283,0.0664379],"study_design_scores_gemma":[0.7942399,0.1206799,0.05639631,0.0003159998,0.01515927,0.000337065,0.0002032649,0.002413152,0.001627611,0.001359143,0.00718781,0.00008051861],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9765538,0.01477302,0.0002520515,0.001513714,0.0002672089,0.0002594648,0.002598171,0.0000943687,0.003688181],"genre_scores_gemma":[0.9899611,0.003375628,0.0002652929,0.0009876878,0.0002556677,0.0003423867,0.002960733,0.00001751987,0.001834018],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00354598,"threshold_uncertainty_score":0.01186246,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2077037832","doi":"10.1016/j.clbc.2013.10.016","title":"Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer","year":2013,"lang":"en","type":"article","venue":"Clinical Breast Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":153,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"Merck","keywords":"Medicine; Capecitabine; Oncology; Breast cancer; Randomized controlled trial; Internal medicine; Cancer; Colorectal cancer","authors":[{"name":"Monica Mita","is_ca":false},{"name":"Anil A. Joy","is_ca":true},{"name":"Alain C. Mita","is_ca":false},{"name":"Kamalesh K. Sankhala","is_ca":false},{"name":"Ying-Ming Jou","is_ca":false},{"name":"Da Zhang","is_ca":false},{"name":"Paul Statkevich","is_ca":false},{"name":"Yali Zhu","is_ca":false},{"name":"Siu‐Long Yao","is_ca":false},{"name":"Karen Small","is_ca":false},{"name":"Rajat Bannerji","is_ca":false},{"name":"Charles L. Shapiro","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02014164253463134,"gpt":0.3471441605379508,"spread":0.3270025180033195,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001516476,0.001886725,0.003547258,0.0004686083,0.0004875189,0.001286798,0.001015351,0.001416397,0.008457474],"category_scores_gemma":[0.001944218,0.0009081569,0.001416043,0.000515894,0.001629685,0.001323525,0.0004950336,0.003928126,0.001176231],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001510864,"about_ca_system_score_gemma":0.00162774,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002071282,"about_ca_topic_score_gemma":0.005411176,"domain_scores_codex":[0.999443,0.0002949073,0.00002647689,0.000106076,0.00002829247,0.0001012874],"domain_scores_gemma":[0.9989443,0.0003129264,0.0001841065,0.00008773196,0.00004984193,0.0004210403],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.984235,0.003738799,0.0002471939,0.0002649607,0.0003503634,0.00002166089,0.00002716786,0.0003939369,0.001369614,0.0001356147,0.0005429303,0.00867278],"study_design_scores_gemma":[0.9643609,0.03384652,0.0005256326,0.00001452785,0.0001713069,0.0000189513,0.00001624707,0.0002980266,0.0001672157,0.0001409617,0.0004319134,0.000007782311],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9827883,0.004852342,0.0008905178,0.001435045,0.001342519,0.003566382,0.001167857,0.0001420616,0.003814969],"genre_scores_gemma":[0.9832023,0.002969391,0.00169297,0.001542526,0.0005954786,0.003159839,0.00135162,0.00004194543,0.005443934],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008457474,"threshold_uncertainty_score":0.02829307,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2805363969","doi":"10.1200/jco.2018.36.18_suppl.lba1006","title":"Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) <i>v</i> FULV in patients (pts) with estrogen receptor (ER)-positive, <i>PIK3CA</i> -mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary; Ottawa Hospital","funders":"","keywords":"Fulvestrant; Medicine; Metastatic breast cancer; Internal medicine; Clinical endpoint; Hazard ratio; Adverse effect; Oncology; Population; Randomized controlled trial; Cancer; Breast cancer; Placebo; Progression-free survival; Estrogen receptor; Confidence interval; Overall survival; Pathology","authors":[{"name":"José Baselga","is_ca":false},{"name":"Susan Dent","is_ca":true},{"name":"Javier Cortés","is_ca":false},{"name":"Young‐Hyuck Im","is_ca":false},{"name":"Véronique Dièras","is_ca":false},{"name":"Nadia Harbeck","is_ca":false},{"name":"Ian E. Krop","is_ca":false},{"name":"Sunil Verma","is_ca":true},{"name":"Timothy R. Wilson","is_ca":false},{"name":"Huan Jin","is_ca":false},{"name":"Lijia Wang","is_ca":false},{"name":"Frauke Schimmöller","is_ca":false},{"name":"Jerry Y. Hsu","is_ca":false},{"name":"Jing He","is_ca":false},{"name":"Michelino De Laurentiis","is_ca":false},{"name":"Pamela Drullinsky","is_ca":false},{"name":"William Jacot","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03734654690843785,"gpt":0.4099493458190268,"spread":0.3726027989105889,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00124702,0.00150046,0.001519012,0.0003959798,0.0003371379,0.0008225086,0.001010405,0.001059666,0.004965354],"category_scores_gemma":[0.0006740913,0.0005670849,0.001227324,0.0004812633,0.0008439348,0.0006727108,0.0003274401,0.002274643,0.001092457],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001378395,"about_ca_system_score_gemma":0.002167469,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002864448,"about_ca_topic_score_gemma":0.007279605,"domain_scores_codex":[0.9997192,0.0001216885,0.0000117458,0.00004865986,0.0000249637,0.00007369483],"domain_scores_gemma":[0.9994018,0.0000783182,0.0001063038,0.00004752514,0.00003300495,0.0003330973],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8655123,0.04183674,0.003267666,0.0005992003,0.001297404,0.0001084134,0.0001576726,0.002139479,0.0295981,0.0002522088,0.00424617,0.05098462],"study_design_scores_gemma":[0.740791,0.2464003,0.006888448,0.00002653465,0.000520169,0.0001222234,0.00004139216,0.0009161463,0.002411452,0.0001751377,0.001687165,0.00001993023],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9872442,0.001706207,0.0007578021,0.0004161946,0.0001297885,0.004553053,0.002531723,0.0002090741,0.002451962],"genre_scores_gemma":[0.9825195,0.001523901,0.001973668,0.0008844542,0.000130813,0.00443649,0.004429926,0.00005273461,0.004048458],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004965354,"threshold_uncertainty_score":0.0166108,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4379645953","doi":"10.1200/jco.2023.41.17_suppl.lba500","title":"Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Letrozole; Breast cancer; Clinical endpoint; Tolerability; Internal medicine; Anastrozole; Population; Oncology; Interim analysis; Goserelin; Cancer; Surgery; Gynecology; Randomized controlled trial; Tamoxifen; Adverse effect","authors":[{"name":"Dennis J. Slamon","is_ca":false},{"name":"Daniil Stroyakovskiy","is_ca":false},{"name":"Denise A. Yardley","is_ca":false},{"name":"Chiun‐Sheng Huang","is_ca":false},{"name":"Peter A. Fasching","is_ca":false},{"name":"John Crown","is_ca":false},{"name":"Aditya Bardia","is_ca":false},{"name":"Stephen Chia","is_ca":true},{"name":"Seock‐Ah Im","is_ca":false},{"name":"Miguel Martín","is_ca":false},{"name":"Sherene Loi","is_ca":false},{"name":"Binghe Xu","is_ca":false},{"name":"Sara A. Hurvitz","is_ca":false},{"name":"Carlos H. Barrios","is_ca":false},{"name":"Michael Untch","is_ca":false},{"name":"Rebecca Moroose","is_ca":false},{"name":"Fran Visco","is_ca":false},{"name":"Rodrigo Fresco","is_ca":false},{"name":"Tetiana Taran","is_ca":false},{"name":"Gabriel N. Hortobágyi","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.07422391342854126,"gpt":0.4508825997255233,"spread":0.3766586862969821,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002200267,0.0009156527,0.001391734,0.0003069431,0.000217242,0.0009104568,0.0006310215,0.0008791805,0.004128017],"category_scores_gemma":[0.001070071,0.0003220175,0.001106863,0.0003814317,0.0004370017,0.0006514746,0.0004192439,0.001706661,0.0008008242],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007228742,"about_ca_system_score_gemma":0.001057977,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008707976,"about_ca_topic_score_gemma":0.00541968,"domain_scores_codex":[0.9995703,0.0002613206,0.00002033135,0.00004205336,0.00003671753,0.00006918539],"domain_scores_gemma":[0.9995614,0.00008916509,0.0001159456,0.0000459272,0.000024917,0.000162626],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8814989,0.0130335,0.006582703,0.001280918,0.002668606,0.0001363518,0.00008709149,0.002044265,0.008918284,0.0003386623,0.008264847,0.07514586],"study_design_scores_gemma":[0.8301743,0.1292258,0.02276908,0.0002001274,0.002721971,0.0002986956,0.00007879339,0.001185461,0.001952311,0.0005296652,0.01082429,0.00003949064],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9458293,0.02664296,0.0009983727,0.00214768,0.0004536403,0.003732994,0.007528778,0.0001674958,0.01249889],"genre_scores_gemma":[0.9686331,0.007118971,0.001735577,0.002659147,0.0004416671,0.00445497,0.0083817,0.00005432507,0.006520533],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004128017,"threshold_uncertainty_score":0.01380956,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2808476554","doi":"10.3747/co.25.3752","title":"Overcoming Endocrine Resistance in Hormone Receptor–Positive Breast Cancer","year":2018,"lang":"en","type":"review","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":false},"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Breast cancer; Hormone receptor; Endocrine system; Hormone; Cancer; Bioinformatics; Resistance (ecology); Receptor; Cancer research; Internal medicine; Oncology; Computational biology; Biology","authors":[{"name":"Ali Al-Fakeeh","is_ca":true},{"name":"Christine Brezden‐Masley","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1127109070422267,"gpt":0.4602473066929266,"spread":0.3475363996506999,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004744043,0.0002320623,0.0004507783,0.0004951483,0.0001833409,0.0005158613,0.0003784643,0.0004268295,0.001833107],"category_scores_gemma":[0.0006903845,0.0001035133,0.0003589607,0.0004379137,0.0002104763,0.0004654923,0.0004363564,0.0009370047,0.0008446412],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005154165,"about_ca_system_score_gemma":0.0004105894,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005324536,"about_ca_topic_score_gemma":0.001332021,"domain_scores_codex":[0.9998404,0.00004479671,0.00001352995,0.00001865931,0.00004862791,0.0000339722],"domain_scores_gemma":[0.9998389,0.00004543021,0.00003148852,0.00001444135,0.0000383234,0.00003129756],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0009335721,0.0004530797,0.005626754,0.002174847,0.0001327466,0.001151323,0.0001677613,0.001778463,0.03253652,0.003264438,0.03544762,0.9163329],"study_design_scores_gemma":[0.0008221649,0.003500414,0.02087929,0.001114764,0.0004128461,0.01308216,0.0004453215,0.004870594,0.03741739,0.008564274,0.9088143,0.00007645702],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.1443218,0.7968711,0.008524428,0.01514119,0.001515944,0.0002336726,0.0005426919,0.0005003848,0.03234882],"genre_scores_gemma":[0.5150976,0.4562132,0.008073383,0.006934185,0.001274937,0.0002453295,0.001395197,0.00006114437,0.01070514],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.001833107,"threshold_uncertainty_score":0.006132364,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2925092419","doi":"10.1056/nejmoa1811714","title":"Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"London Health Sciences Centre; Cancer Care Ontario","funders":"National Cancer Institute","keywords":"Anastrozole; Fulvestrant; Medicine; Oncology; Aromatase inhibitor; Metastatic breast cancer; Internal medicine; Aromatase; Breast cancer; Cancer; Tamoxifen; Estrogen receptor; Progression-free survival; Overall survival","authors":[{"name":"Rita S. Mehta","is_ca":true},{"name":"William E. Barlow","is_ca":true},{"name":"Kathy S. Albain","is_ca":true},{"name":"Ted Vandenberg","is_ca":true},{"name":"Shaker R. Dakhil","is_ca":true},{"name":"Nagendra R. Tirumali","is_ca":true},{"name":"Danika L. Lew","is_ca":true},{"name":"Daniel F. Hayes","is_ca":true},{"name":"Julie R. Gralow","is_ca":true},{"name":"Hannah M. Linden","is_ca":true},{"name":"Robert B. Livingston","is_ca":true},{"name":"Gabriel N. Hortobágyi","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01613558606668913,"gpt":0.2899758635197193,"spread":0.2738402774530302,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009748111,0.0002569508,0.0005275767,0.0002937484,0.000101,0.0001545311,0.0001880795,0.0002009942,0.0007936644],"category_scores_gemma":[0.001441635,0.00006632924,0.0006142986,0.0002544752,0.0001818199,0.0002015873,0.0002101725,0.0002800689,0.0000789917],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003900675,"about_ca_system_score_gemma":0.00030085,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003548351,"about_ca_topic_score_gemma":0.0009689337,"domain_scores_codex":[0.999716,0.0001329889,0.00002241753,0.00003761903,0.00005023053,0.00004084079],"domain_scores_gemma":[0.9995759,0.0001752825,0.0001297912,0.000024048,0.00002109725,0.00007388044],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2631907,0.002588833,0.1920817,0.001899572,0.003687676,0.0007561689,0.0002855343,0.01074665,0.03501335,0.0002880621,0.001987866,0.4874739],"study_design_scores_gemma":[0.02904582,0.3294912,0.6085448,0.0003511689,0.004623204,0.002243575,0.0001285425,0.005067179,0.01163463,0.001310132,0.007514417,0.00004527036],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9923975,0.006639438,0.0002819118,0.0001541778,0.00002690225,0.00003276326,0.0000927914,0.00001346449,0.0003611368],"genre_scores_gemma":[0.9980302,0.001400345,0.0001803772,0.00005546933,0.00004515232,0.00003221675,0.0001747709,0.000001291738,0.00008003627],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0009748111,"threshold_uncertainty_score":0.005155325,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2149472508","doi":"10.1007/s10637-007-9090-3","title":"A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors","year":2007,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Pyrogenesis (Canada)","funders":"","keywords":"Pharmacokinetics; Cmax; Medicine; Tolerability; Bioavailability; Nausea; Adverse effect; Pharmacology; Pharmacodynamics; Maximum tolerated dose; Cyclin-dependent kinase; Dysgeusia; Toxicity; Refractory (planetary science); Oral administration; Internal medicine; Cancer; Cell cycle","authors":[{"name":"Elisabeth I. Heath","is_ca":false},{"name":"Keith C. Bible","is_ca":false},{"name":"Robert E. Martell","is_ca":true},{"name":"Daniel C. Adelman","is_ca":false},{"name":"Patricia LoRusso","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02381757120153434,"gpt":0.3125895757310258,"spread":0.2887720045294915,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001635189,0.002271293,0.002580162,0.0007906793,0.000595008,0.0009543988,0.001191539,0.001601028,0.004248644],"category_scores_gemma":[0.001033831,0.0009039931,0.001570868,0.0005615705,0.001557796,0.001036535,0.0003393466,0.004431476,0.00105777],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001084324,"about_ca_system_score_gemma":0.002696188,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002411867,"about_ca_topic_score_gemma":0.007041622,"domain_scores_codex":[0.9995448,0.0002233243,0.00001280033,0.00007223982,0.00004037204,0.0001064363],"domain_scores_gemma":[0.9992385,0.0001587834,0.00008857439,0.00006029831,0.00003858378,0.0004152101],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6619341,0.1365551,0.005351201,0.000903803,0.001448444,0.0005040853,0.0005770196,0.005920904,0.07856636,0.0009788224,0.01097191,0.09628828],"study_design_scores_gemma":[0.5571852,0.4229033,0.00623882,0.00002724442,0.0004611403,0.000422429,0.00009726492,0.001906259,0.006479457,0.0003606356,0.003878377,0.00003989723],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9879522,0.001995121,0.0009989797,0.0009566107,0.000273222,0.002550493,0.001891814,0.0001507936,0.003230859],"genre_scores_gemma":[0.9752666,0.003319918,0.003351347,0.001611239,0.0003944143,0.003983098,0.005334057,0.0001027092,0.00663673],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004248644,"threshold_uncertainty_score":0.01421314,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2037157828","doi":"10.1016/j.clbc.2013.08.011","title":"Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptor–Positive Breast Cancer in BOLERO-2","year":2013,"lang":"en","type":"article","venue":"Clinical Breast Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary; Sunnybrook Health Science Centre; University of Toronto","funders":"Novartis Pharmaceuticals Corporation; Pfizer","keywords":"Exemestane; Medicine; Everolimus; Breast cancer; Oncology; Internal medicine; Hormone receptor; Aromatase; Cancer; Gynecology","authors":[{"name":"Kathleen I. Pritchard","is_ca":true},{"name":"Howard A. Burris","is_ca":false},{"name":"Yoshinori Ito","is_ca":false},{"name":"Hope S. Rugo","is_ca":false},{"name":"Shaker R. Dakhil","is_ca":false},{"name":"Gabriel N. Hortobágyi","is_ca":false},{"name":"Mario Campone","is_ca":false},{"name":"Tibor Csőszi","is_ca":false},{"name":"José Baselga","is_ca":false},{"name":"Puttisak Puttawibul","is_ca":false},{"name":"Martine Piccart","is_ca":false},{"name":"Daniel Y.C. Heng","is_ca":true},{"name":"Shinzaburo Noguchi","is_ca":false},{"name":"Vichien Srimuninnimit","is_ca":false},{"name":"Hugues Bourgeois","is_ca":false},{"name":"Antonio González-Martı́n","is_ca":false},{"name":"Karen A. Osborne","is_ca":false},{"name":"Ashok Panneerselvam","is_ca":false},{"name":"Tetiana Taran","is_ca":false},{"name":"Tarek Sahmoud","is_ca":false},{"name":"Michael Gnant","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.009278835326357648,"gpt":0.2903044741973232,"spread":0.2810256388709656,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001554842,0.0004983817,0.001818113,0.0003243827,0.0002397042,0.0007979677,0.0004882879,0.0006577671,0.002200675],"category_scores_gemma":[0.001533663,0.0003190138,0.001534429,0.0003450712,0.0004307371,0.0007253655,0.0004437484,0.00153675,0.0003462535],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007980281,"about_ca_system_score_gemma":0.0008219046,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004366038,"about_ca_topic_score_gemma":0.001508225,"domain_scores_codex":[0.9996005,0.0001773496,0.00004626786,0.00007514757,0.00004701794,0.00005380501],"domain_scores_gemma":[0.9992817,0.0001454101,0.0002556929,0.00003664761,0.00002807475,0.0002524505],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9318219,0.004975503,0.01238746,0.0006041335,0.0017351,0.0001150855,0.00008391479,0.0008073614,0.006543196,0.00007245078,0.0007957037,0.04005833],"study_design_scores_gemma":[0.6227151,0.2846884,0.0817662,0.0002279487,0.003479984,0.0003925357,0.00009028526,0.001182222,0.002091313,0.0001881649,0.003130436,0.00004738721],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9885858,0.009256128,0.00009070196,0.0002423679,0.00007893109,0.0002256598,0.0004501313,0.00001575394,0.001054564],"genre_scores_gemma":[0.9935725,0.003192728,0.0003541521,0.0005838145,0.00015515,0.0003004583,0.001063398,0.000006572522,0.0007713348],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002200675,"threshold_uncertainty_score":0.008222938,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2783341375","doi":"10.1093/annonc/mdx797","title":"Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"Pfizer","keywords":"Palbociclib; Medicine; Letrozole; Fulvestrant; Internal medicine; Hazard ratio; Breast cancer; Oncology; Metastatic breast cancer; Cancer; Placebo; Gynecology; Gastroenterology; Confidence interval; Estrogen receptor; Tamoxifen; Pathology","authors":[{"name":"Nicholas C. Turner","is_ca":false},{"name":"Richard S. Finn","is_ca":false},{"name":"Miguel Martín","is_ca":false},{"name":"Seock‐Ah Im","is_ca":false},{"name":"Angela DeMichele","is_ca":false},{"name":"Johannes Ettl","is_ca":false},{"name":"Véronique Dièras","is_ca":false},{"name":"Stacy Moulder","is_ca":false},{"name":"Oleg Lipatov","is_ca":false},{"name":"Marco Colleoni","is_ca":false},{"name":"Massimo Cristofanilli","is_ca":false},{"name":"Dongrui R. Lu","is_ca":false},{"name":"A. Mori","is_ca":false},{"name":"C. Giorgetti","is_ca":false},{"name":"Shrividya Iyer","is_ca":false},{"name":"C Huang Bartlett","is_ca":false},{"name":"Karen A. Gelmon","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04509901211439402,"gpt":0.4148736468886414,"spread":0.3697746347742473,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005446516,0.0005195502,0.001700489,0.000802542,0.0008745035,0.003991078,0.001149363,0.002707385,0.003353224],"category_scores_gemma":[0.01355479,0.0003133917,0.001044239,0.0005624442,0.001391915,0.002532453,0.001129823,0.006579753,0.0009982454],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001853841,"about_ca_system_score_gemma":0.003454608,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002015472,"about_ca_topic_score_gemma":0.008619862,"domain_scores_codex":[0.9977963,0.001064259,0.0003170022,0.0001786642,0.0004764931,0.0001673316],"domain_scores_gemma":[0.9951295,0.002570064,0.0004980959,0.0001104533,0.00091866,0.0007732913],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.007311496,0.000488131,0.04052508,0.001949738,0.0004584299,0.009894444,0.0006839617,0.004629351,0.005521352,0.01668942,0.06814072,0.8437078],"study_design_scores_gemma":[0.005696949,0.01108142,0.1308487,0.01163353,0.002015362,0.08329162,0.007617608,0.01466067,0.004286901,0.05768484,0.6706869,0.0004955163],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.07538127,0.4215031,0.005600872,0.3993128,0.005955366,0.0002923741,0.0006319887,0.0001467026,0.09117547],"genre_scores_gemma":[0.6536832,0.1843985,0.01513661,0.1063998,0.03179226,0.000486403,0.000841738,0.0001133957,0.007148008],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.005446516,"threshold_uncertainty_score":0.02880424,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4410927250","doi":"10.1056/nejmoa2502929","title":"First-Line Camizestrant for Emerging <i>ESR1</i> -Mutated Advanced Breast Cancer","year":2025,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"Agence Nationale de la Recherche; AstraZeneca","keywords":"Breast cancer; Line (geometry); Oncology; Cancer research; Cancer; Computational biology; Medicine; Biology; Internal medicine; Mathematics","authors":[{"name":"François‐Clément Bidard","is_ca":false},{"name":"Erica L. Mayer","is_ca":false},{"name":"Yeon Hee Park","is_ca":false},{"name":"Wolfgang Janni","is_ca":false},{"name":"X. Cynthia","is_ca":false},{"name":"Massimo Cristofanilli","is_ca":false},{"name":"Giampaolo Bianchini","is_ca":false},{"name":"Kevin Kalinsky","is_ca":false},{"name":"Hiroji Iwata","is_ca":false},{"name":"Stephen Chia","is_ca":true},{"name":"Peter A. Fasching","is_ca":false},{"name":"Adam Brufsky","is_ca":false},{"name":"Zbigniew Nowecki","is_ca":false},{"name":"Javier Pascual","is_ca":false},{"name":"L. Moreau","is_ca":false},{"name":"Shin-Cheh Chen","is_ca":false},{"name":"Nuri Karadurmuş","is_ca":false},{"name":"Einav Nili Gal‐Yam","is_ca":false},{"name":"Kyung Hae Jung","is_ca":false},{"name":"Sònia Pernas","is_ca":false},{"name":"Sasha McClain","is_ca":false},{"name":"Wei He","is_ca":false},{"name":"Teresa Klinowska","is_ca":false},{"name":"Cynthia Huang Bartlett","is_ca":false},{"name":"Nicholas C. Turner","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01292950396255306,"gpt":0.3241416641217435,"spread":0.3112121601591905,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003617863,0.0002210306,0.0005611131,0.0001477547,0.0001577072,0.0002247978,0.0002150989,0.000213633,0.004675095],"category_scores_gemma":[0.0005407193,0.00006081304,0.000461882,0.000140004,0.0001646935,0.0001606297,0.0001061916,0.0004715758,0.0003977113],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000454555,"about_ca_system_score_gemma":0.0003600495,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002760073,"about_ca_topic_score_gemma":0.001427972,"domain_scores_codex":[0.9998794,0.00003551805,0.00001139863,0.00002334118,0.00002568487,0.00002472171],"domain_scores_gemma":[0.9997001,0.00008512352,0.000107784,0.00001693131,0.00001519271,0.00007506482],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1669811,0.003876996,0.1339026,0.001820525,0.001596072,0.001457726,0.0002351677,0.001974765,0.05077161,0.0008509623,0.008093888,0.6284386],"study_design_scores_gemma":[0.1196194,0.1871035,0.5539659,0.0007038238,0.002923019,0.01343561,0.0003854993,0.003335795,0.04751264,0.001823877,0.06911819,0.00007265164],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9885762,0.006874372,0.0004212945,0.0002810674,0.00008156535,0.0002676614,0.0004694402,0.00003091593,0.002997553],"genre_scores_gemma":[0.99557,0.001796663,0.0004893109,0.0002715132,0.0000769542,0.0001435043,0.0006742825,0.000004993354,0.0009728864],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004675095,"threshold_uncertainty_score":0.01563972,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2702886506","doi":"10.1200/jco.2016.34.15_suppl.507","title":"PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Palbociclib; Letrozole; Clinical endpoint; Internal medicine; Hazard ratio; Breast cancer; Cancer; Progression-free survival; Adverse effect; Oncology; Gynecology; Randomized controlled trial; Metastatic breast cancer; Confidence interval; Tamoxifen; Overall survival","authors":[{"name":"Richard S. Finn","is_ca":false},{"name":"Miguel Martín","is_ca":false},{"name":"Hope S. Rugo","is_ca":false},{"name":"Stephen E. Jones","is_ca":false},{"name":"Seock‐Ah Im","is_ca":false},{"name":"Karen A. Gelmon","is_ca":true},{"name":"Nadia Harbeck","is_ca":false},{"name":"Oleg Lipatov","is_ca":false},{"name":"Janice M. Walshe","is_ca":false},{"name":"Stacy Moulder","is_ca":false},{"name":"Eric Gauthier","is_ca":false},{"name":"Dongrui R. Lu","is_ca":false},{"name":"Sophia Randolph","is_ca":false},{"name":"Véronique Dièras","is_ca":false},{"name":"Dennis J. Slamon","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04252982893718386,"gpt":0.4039353674576152,"spread":0.3614055385204313,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002947318,0.002786407,0.002498732,0.0006012465,0.0004996124,0.001307894,0.001623978,0.001753022,0.01240392],"category_scores_gemma":[0.002396998,0.0008255018,0.002162189,0.0004553862,0.001176036,0.001282956,0.0006705477,0.004720429,0.002202464],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001069115,"about_ca_system_score_gemma":0.001894626,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001189312,"about_ca_topic_score_gemma":0.003213449,"domain_scores_codex":[0.9993193,0.0003759601,0.00002988705,0.00009229517,0.00005800308,0.0001245066],"domain_scores_gemma":[0.9987069,0.0003623793,0.0002665375,0.00009616841,0.00007484856,0.00049311],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9586694,0.01449507,0.0008010321,0.0006121861,0.0008638413,0.00007503835,0.00005902146,0.0004124904,0.004100903,0.00008862876,0.002727336,0.01709508],"study_design_scores_gemma":[0.904254,0.09119442,0.002184791,0.00003093253,0.0005115044,0.00007437033,0.00002136867,0.0002735289,0.0004987855,0.0001296129,0.0008141801,0.00001255115],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9641553,0.006350478,0.001065438,0.001590744,0.0004516485,0.009746837,0.008898318,0.0003790317,0.007362268],"genre_scores_gemma":[0.9690964,0.002951476,0.001830904,0.001948428,0.0006169383,0.008823218,0.008381584,0.00009344734,0.006257636],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01240392,"threshold_uncertainty_score":0.04149532,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1558355135","doi":"10.1002/cncr.28010","title":"Health‐related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO‐2 trial","year":2013,"lang":"en","type":"article","venue":"Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Cambridge Memorial Hospital","funders":"National Cancer Institute; Sanofi; Celgene; AstraZeneca; Chugai Pharmaceutical; Amgen; Pfizer; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Medicine; Exemestane; Everolimus; Breast cancer; Internal medicine; Quality of life (healthcare); Placebo; Discontinuation; Oncology; Hazard ratio; Clinical endpoint; Randomized controlled trial; Aromatase inhibitor; Cancer; Gynecology; Confidence interval; Tamoxifen; Pathology","authors":[{"name":"Howard A. Burris","is_ca":false},{"name":"Fabienne Lebrun","is_ca":false},{"name":"Hope S. Rugo","is_ca":false},{"name":"J. Thaddeus Beck","is_ca":false},{"name":"Martine Piccart","is_ca":false},{"name":"Patrick Neven","is_ca":false},{"name":"José Baselga","is_ca":false},{"name":"Katarína Petráková","is_ca":false},{"name":"Gabriel N. Hortobágyi","is_ca":false},{"name":"Anna W. Komorowski","is_ca":false},{"name":"E. Chouinard","is_ca":true},{"name":"Robyn R. Young","is_ca":false},{"name":"Michael Gnant","is_ca":false},{"name":"Kathleen I. Pritchard","is_ca":true},{"name":"L. Michelle Bennett","is_ca":false},{"name":"Jean‐Francois Ricci","is_ca":false},{"name":"H. Bauly","is_ca":false},{"name":"Tetiana Taran","is_ca":false},{"name":"Tarek Sahmoud","is_ca":false},{"name":"Shinzaburo Noguchi","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02037856840053433,"gpt":0.3230547976171125,"spread":0.3026762292165782,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003089526,0.001261598,0.002803857,0.0003497622,0.0003423548,0.001278451,0.0007198817,0.001332606,0.004141468],"category_scores_gemma":[0.002273032,0.0004591249,0.002985351,0.0003400199,0.0007537305,0.0007451472,0.0005010191,0.00284816,0.0004339853],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007038524,"about_ca_system_score_gemma":0.0008119479,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000539265,"about_ca_topic_score_gemma":0.001223804,"domain_scores_codex":[0.9986046,0.0009614991,0.00009152914,0.0001549725,0.00009146011,0.00009598705],"domain_scores_gemma":[0.9990232,0.0003048756,0.0003520906,0.00005423736,0.00004970474,0.0002159312],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9871395,0.001880967,0.001136554,0.0006696789,0.001955004,0.0000176934,0.00002503507,0.0002132219,0.0007575972,0.00005125374,0.0004419286,0.005711485],"study_design_scores_gemma":[0.9485454,0.04341786,0.005206986,0.00008297664,0.001399843,0.00003198184,0.00001641785,0.0002707021,0.0002577602,0.0001408148,0.0006153216,0.00001383859],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9735657,0.01824179,0.0004097101,0.001170431,0.0007233369,0.002192373,0.001467193,0.00006014793,0.002169207],"genre_scores_gemma":[0.9875987,0.003845894,0.0008757184,0.001138745,0.0005019681,0.002958496,0.001445879,0.00001174181,0.001622814],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004141468,"threshold_uncertainty_score":0.01633918,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2060696690","doi":"10.1016/j.lungcan.2013.11.020","title":"Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer","year":2013,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"Merck Sharp and Dohme","keywords":"Medicine; Erlotinib; Internal medicine; Neutropenia; Oncology; Lung cancer; Adverse effect; Surgery; Cancer; Epidermal growth factor receptor; Chemotherapy","authors":[{"name":"Joe Stephenson","is_ca":false},{"name":"John Nemunaitis","is_ca":false},{"name":"Anil A. Joy","is_ca":true},{"name":"Julie Martin","is_ca":false},{"name":"Ying‐Ming Jou","is_ca":false},{"name":"Da Zhang","is_ca":false},{"name":"Paul Statkevich","is_ca":false},{"name":"Siu‐Long Yao","is_ca":false},{"name":"Yali Zhu","is_ca":false},{"name":"Karen Small","is_ca":false},{"name":"Rajat Bannerji","is_ca":false},{"name":"Martin J. Edelman","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.009580312840794003,"gpt":0.2976431150917498,"spread":0.2880628022509558,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001447556,0.001948596,0.003435514,0.0004517126,0.0004626356,0.001376361,0.001031259,0.001546269,0.008561474],"category_scores_gemma":[0.001711188,0.001054103,0.001677013,0.0004366515,0.001378002,0.001630137,0.000494974,0.003858104,0.001366813],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001538908,"about_ca_system_score_gemma":0.001555117,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001781268,"about_ca_topic_score_gemma":0.005387852,"domain_scores_codex":[0.9994641,0.0002714458,0.00002352886,0.00009973948,0.00003086442,0.0001104271],"domain_scores_gemma":[0.9992111,0.0002148836,0.0001470368,0.0000717123,0.00004874002,0.0003066524],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9812348,0.004568965,0.0003711271,0.000270588,0.0004932536,0.000024931,0.00003239276,0.0004947301,0.00173164,0.0001383945,0.0007470534,0.009892122],"study_design_scores_gemma":[0.9610425,0.03643491,0.0008297262,0.00001398337,0.0002407279,0.00002537321,0.00002025991,0.0004070912,0.0002211358,0.0001687644,0.0005837553,0.00001178589],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9851163,0.003458725,0.0008155112,0.001179394,0.001014567,0.00312818,0.001549182,0.0001694264,0.003568846],"genre_scores_gemma":[0.9844563,0.002086947,0.001595245,0.00151547,0.0005048842,0.003305251,0.001597249,0.00005178495,0.004886934],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008561474,"threshold_uncertainty_score":0.02864093,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4379508645","doi":"10.1177/17588359231178125","title":"Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy <i>versus</i> endocrine therapy alone in patients with HR+/HER2− early breast cancer","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"Genentech; PharmaMar; Novartis Institutes for BioMedical Research; Daewoong Pharmaceutical Company; Astellas Pharma; Eisai; Seagen; Mersana Therapeutics; Mylan; Syndax Pharmaceuticals; Clovis Oncology; Astex Pharmaceuticals; Merck KGaA; Taiho Pharmaceutical; F. Hoffmann-La Roche; Amgen; Radius Health; Daiichi Sankyo Europe; LEO Pharma; Gilead Sciences; Exelixis; Sanofi; Pfizer; Novartis Pharmaceuticals Corporation; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Letrozole; Internal medicine; Breast cancer; Clinical endpoint; Oncology; Anastrozole; Palbociclib; Metastatic breast cancer; Goserelin; Randomization; Cancer; Adjuvant therapy; Clinical trial; Tamoxifen; Gynecology","authors":[{"name":"Dennis J. Slamon","is_ca":false},{"name":"Peter A. Fasching","is_ca":false},{"name":"Sara A. Hurvitz","is_ca":false},{"name":"Stephen Chia","is_ca":true},{"name":"John Crown","is_ca":false},{"name":"Miguel Martín","is_ca":false},{"name":"Carlos H. Barrios","is_ca":false},{"name":"Aditya Bardia","is_ca":false},{"name":"Seock‐Ah Im","is_ca":false},{"name":"Denise A. Yardley","is_ca":false},{"name":"Michael Untch","is_ca":false},{"name":"Chiun‐Sheng Huang","is_ca":false},{"name":"Daniil Stroyakovskiy","is_ca":false},{"name":"Binghe Xu","is_ca":false},{"name":"Rebecca Moroose","is_ca":false},{"name":"Sherene Loi","is_ca":false},{"name":"F. Visco","is_ca":false},{"name":"Valerie Bee-Munteanu","is_ca":false},{"name":"Karen Afenjar","is_ca":false},{"name":"Rodrigo Fresco","is_ca":false},{"name":"Tetiana Taran","is_ca":false},{"name":"Arunava Chakravartty","is_ca":false},{"name":"Juan Pablo Zarate","is_ca":false},{"name":"Agnes Lteif","is_ca":false},{"name":"Gabriel N. Hortobágyi","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0373529934834873,"gpt":0.3836976276393478,"spread":0.3463446341558605,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.05800121,0.003357145,0.003894784,0.001853755,0.002583153,0.003267252,0.003411683,0.005822005,0.01785388],"category_scores_gemma":[0.04148613,0.002236635,0.002328791,0.001850667,0.004834429,0.002636118,0.001671823,0.007815777,0.007986967],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002501612,"about_ca_system_score_gemma":0.01003338,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008789632,"about_ca_topic_score_gemma":0.002598859,"domain_scores_codex":[0.9546955,0.03358844,0.002974551,0.003994824,0.003463443,0.001283242],"domain_scores_gemma":[0.9860729,0.0040328,0.002290313,0.001765833,0.002588658,0.003249435],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4644683,0.01217517,0.01318074,0.02352776,0.003882352,0.001896708,0.001669504,0.006055474,0.009857903,0.1028022,0.1472718,0.213212],"study_design_scores_gemma":[0.52255,0.04392109,0.01298686,0.01038778,0.003132429,0.001043893,0.000454838,0.01058373,0.003594934,0.04869352,0.3421746,0.0004762225],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.01051211,0.006296942,0.02217999,0.01112265,0.006684751,0.9250506,0.004355012,0.0003483212,0.01344972],"genre_scores_gemma":[0.02836167,0.001355903,0.02812693,0.01013178,0.001330624,0.9270746,0.001007671,0.00004518596,0.002565662],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.05800121,"threshold_uncertainty_score":0.3067434,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2884436796","doi":"10.1093/jnci/djy109","title":"Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer","year":2018,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"David Geffen School of Medicine, University of California, Los Angeles; BC Cancer Agency; Robert H. Lurie Comprehensive Cancer Center; Russian Science Foundation; Peter MacCallum Cancer Centre; Feinberg School of Medicine; Pfizer","keywords":"Palbociclib; Fulvestrant; Letrozole; Medicine; Internal medicine; Adverse effect; Breast cancer; Oncology; Placebo; Neutropenia; Metastatic breast cancer; Cancer; Gynecology; Chemotherapy; Tamoxifen","authors":[{"name":"Véronique Dièras","is_ca":false},{"name":"Hope S. Rugo","is_ca":false},{"name":"Patrick Schnell","is_ca":false},{"name":"Karen A. Gelmon","is_ca":true},{"name":"Massimo Cristofanilli","is_ca":false},{"name":"Sherene Loi","is_ca":false},{"name":"Marco Colleoni","is_ca":false},{"name":"Dongrui R. Lu","is_ca":false},{"name":"A. Mori","is_ca":false},{"name":"Eric Gauthier","is_ca":false},{"name":"Cynthia Huang Bartlett","is_ca":false},{"name":"Dennis J. Slamon","is_ca":false},{"name":"Nicholas C. Turner","is_ca":false},{"name":"Richard S. Finn","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0272881053857524,"gpt":0.3613495205114768,"spread":0.3340614151257245,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04024173,0.00167218,0.005187943,0.002352342,0.0003675946,0.002428021,0.001056107,0.001138168,0.002121165],"category_scores_gemma":[0.03716215,0.0008400589,0.01772398,0.002627328,0.0004688094,0.001182727,0.00130662,0.001199837,0.0004312756],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001402416,"about_ca_system_score_gemma":0.001725034,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001197528,"about_ca_topic_score_gemma":0.001587794,"domain_scores_codex":[0.9804545,0.01116577,0.002657766,0.002518983,0.002816437,0.000386523],"domain_scores_gemma":[0.9645625,0.01374339,0.01262758,0.003736554,0.004778957,0.0005509923],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"observational","study_design_scores_codex":[0.1148629,0.0004230281,0.07947932,0.01012049,0.7430017,0.0002147467,0.000127298,0.004846106,0.005073327,0.0001424694,0.00245111,0.03925754],"study_design_scores_gemma":[0.01721933,0.02271356,0.2605844,0.0009715282,0.679347,0.000848292,0.0001500811,0.005503476,0.004175715,0.0005996447,0.007731985,0.00015497],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7254573,0.2291535,0.0146076,0.000721235,0.0006718259,0.002209782,0.02318596,0.0005578042,0.00343507],"genre_scores_gemma":[0.978613,0.008181168,0.002008061,0.0005154319,0.000319582,0.001110412,0.008566218,0.00006979545,0.0006164619],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04024173,"threshold_uncertainty_score":0.2128212,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2950856878","doi":"10.1634/theoncologist.2019-0019","title":"Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; University of Calgary; University of Alberta","funders":"Genentech; Pfizer","keywords":"Letrozole; Palbociclib; Medicine; Oncology; Internal medicine; Postmenopausal women; Randomized controlled trial; Breast cancer; Cancer; Gynecology; Tamoxifen; Metastatic breast cancer","authors":[{"name":"Véronique Dièras","is_ca":false},{"name":"Nadia Harbeck","is_ca":false},{"name":"Anil A. Joy","is_ca":true},{"name":"Karen A. Gelmon","is_ca":true},{"name":"Johannes Ettl","is_ca":false},{"name":"Sunil Verma","is_ca":true},{"name":"Dongrui R. Lu","is_ca":false},{"name":"Eric Gauthier","is_ca":false},{"name":"Patrick Schnell","is_ca":false},{"name":"A. Mori","is_ca":false},{"name":"Hope S. Rugo","is_ca":false},{"name":"Richard S. Finn","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.006386544342530553,"gpt":0.2729757012801935,"spread":0.2665891569376629,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00234526,0.0008851025,0.001456029,0.00036814,0.0002305206,0.0009441709,0.0006850747,0.00102747,0.004460609],"category_scores_gemma":[0.002528443,0.0003740105,0.001563709,0.0003987063,0.0005145484,0.0006684886,0.0003844256,0.002072213,0.0004398312],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006839891,"about_ca_system_score_gemma":0.001089673,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005938301,"about_ca_topic_score_gemma":0.001632829,"domain_scores_codex":[0.998934,0.0007505612,0.00005428851,0.0001040426,0.00009485355,0.00006223431],"domain_scores_gemma":[0.9992251,0.0002534795,0.0002540816,0.00005094744,0.00006423915,0.0001521716],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9454441,0.002981177,0.002346808,0.001385669,0.002949998,0.00008186959,0.00004196246,0.0008672398,0.003980536,0.000238778,0.00236113,0.03732081],"study_design_scores_gemma":[0.9348662,0.05464932,0.004312522,0.0001018279,0.001930658,0.0001113993,0.00002771382,0.0007292224,0.0007452311,0.0003389392,0.002172457,0.00001442686],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9602706,0.02424049,0.001139385,0.001806331,0.0004309026,0.00397395,0.00263492,0.00019145,0.005311972],"genre_scores_gemma":[0.9853219,0.005243612,0.0008664511,0.00140759,0.0004013648,0.003042973,0.001699862,0.00002356011,0.001992677],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004460609,"threshold_uncertainty_score":0.0149222,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2798042703","doi":"10.1007/s10549-018-4769-z","title":"Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2","year":2018,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"Novartis Institutes for BioMedical Research; Astex Pharmaceuticals; Novartis Pharmaceuticals Corporation","keywords":"Letrozole; Medicine; Breast cancer; Internal medicine; Quality of life (healthcare); Placebo; Oncology; Cancer; Gynecology; Tamoxifen; Pathology","authors":[{"name":"Sunil Verma","is_ca":true},{"name":"Joyce O’Shaughnessy","is_ca":false},{"name":"Howard A. Burris","is_ca":false},{"name":"Mario Campone","is_ca":false},{"name":"Emilio Alba","is_ca":false},{"name":"David Chandiwana","is_ca":false},{"name":"Anand A. Dalal","is_ca":false},{"name":"Santosh Sutradhar","is_ca":false},{"name":"Mauricio Monaco","is_ca":false},{"name":"Wolfgang Janni","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04369723222632609,"gpt":0.3575200797900653,"spread":0.3138228475637392,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001053325,0.0003568432,0.0007962885,0.0001669792,0.0001173826,0.000330109,0.0002633859,0.0003349016,0.001129502],"category_scores_gemma":[0.0007958057,0.0001320645,0.0009280571,0.0001924054,0.0001676059,0.0001841981,0.0002438754,0.0004937636,0.0001765947],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003954899,"about_ca_system_score_gemma":0.0003906205,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009615793,"about_ca_topic_score_gemma":0.002429457,"domain_scores_codex":[0.9997599,0.0001140605,0.0000161537,0.00003605989,0.00004499897,0.00002878613],"domain_scores_gemma":[0.9997148,0.00005200239,0.0001103507,0.00002131042,0.00002448159,0.00007709931],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4868087,0.008471862,0.2784028,0.001385052,0.007163472,0.0002026801,0.0002835268,0.002010334,0.01999637,0.00006807553,0.002788387,0.1924187],"study_design_scores_gemma":[0.04814794,0.08764435,0.853568,0.00009598367,0.003731701,0.0003320004,0.00008620536,0.001268052,0.001989028,0.00007366085,0.003031918,0.00003113543],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9964387,0.00250697,0.00005041621,0.0001099173,0.00001012478,0.00005651757,0.0004943557,0.000006437912,0.0003266261],"genre_scores_gemma":[0.9975094,0.0008141674,0.0001125717,0.0001677607,0.00002107272,0.00007546977,0.0008915699,0.00000203326,0.0004060687],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001129502,"threshold_uncertainty_score":0.005570531,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2765692744","doi":"10.1007/s10549-017-4523-y","title":"Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial","year":2017,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital; University of Ottawa; Occupational Cancer Research Centre","funders":"Novartis Institutes for BioMedical Research; Astex Pharmaceuticals; Novartis Pharmaceuticals Corporation","keywords":"Letrozole; Medicine; Breast cancer; Hazard ratio; Discontinuation; Internal medicine; Placebo; Metastatic breast cancer; Clinical endpoint; Population; Nausea; Oncology; Cancer; Surgery; Randomized controlled trial; Tamoxifen; Confidence interval","authors":[{"name":"Gabe S. Sonke","is_ca":false},{"name":"Lowell L. Hart","is_ca":false},{"name":"Mario Campone","is_ca":false},{"name":"Frans Erdkamp","is_ca":false},{"name":"Wolfgang Janni","is_ca":false},{"name":"Sunil Verma","is_ca":true},{"name":"Cristian Villanueva","is_ca":false},{"name":"Erik Jakobsen","is_ca":false},{"name":"Emilio Alba","is_ca":false},{"name":"Erik Wist","is_ca":false},{"name":"Anne Favret","is_ca":false},{"name":"Thomas Bachelot","is_ca":false},{"name":"Roberto Hegg","is_ca":false},{"name":"Paul Wheatley‐Price","is_ca":true},{"name":"Farida Souami","is_ca":false},{"name":"Santosh Sutradhar","is_ca":false},{"name":"Michelle C. Miller","is_ca":false},{"name":"Caroline Germa","is_ca":false},{"name":"Howard A. Burris","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02442456894890639,"gpt":0.337798520493771,"spread":0.3133739515448646,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001337191,0.0007853695,0.001300102,0.0002098291,0.0001580953,0.0006057099,0.0003977794,0.0006634598,0.002865632],"category_scores_gemma":[0.001082896,0.0002151514,0.001465073,0.0002022445,0.0002945047,0.0003967977,0.000337958,0.001311534,0.0003496869],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005373004,"about_ca_system_score_gemma":0.0006712734,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000655772,"about_ca_topic_score_gemma":0.002647806,"domain_scores_codex":[0.9996568,0.0002147989,0.00001960983,0.00004306454,0.00002627817,0.00003933235],"domain_scores_gemma":[0.9996411,0.0000701485,0.0001249664,0.0000258216,0.00001954164,0.0001184539],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9677117,0.001699419,0.002564225,0.0005404291,0.001979991,0.00006780029,0.00003103652,0.0005590231,0.002856544,0.0001056241,0.00153615,0.02034802],"study_design_scores_gemma":[0.8998716,0.07773846,0.01443751,0.0001146096,0.00252049,0.0001682902,0.00003996039,0.0009913016,0.0007808327,0.0002787572,0.003037961,0.00002011783],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9802772,0.01350684,0.0003048263,0.0009574082,0.0003791845,0.000795949,0.001125511,0.00006625622,0.002586735],"genre_scores_gemma":[0.9892241,0.003542258,0.0004953885,0.001208112,0.0003885899,0.001009215,0.001615016,0.000009882239,0.00250746],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002865632,"threshold_uncertainty_score":0.009586513,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3049702673","doi":"10.1016/j.ctrv.2020.102086","title":"Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis","year":2020,"lang":"en","type":"article","venue":"Cancer Treatment Reviews","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Palbociclib; Medicine; Fulvestrant; Tolerability; Metastatic breast cancer; Internal medicine; Oncology; Adverse effect; Neutropenia; Discontinuation; Breast cancer; Hazard ratio; Pharmacology; Cancer; Chemotherapy; Estrogen receptor; Confidence interval","authors":[{"name":"Alexandra Desnoyers","is_ca":true},{"name":"Michelle B. Nadler","is_ca":true},{"name":"Vikaash Kumar","is_ca":true},{"name":"Ramy Saleh","is_ca":true},{"name":"Eitan Amir","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1381587461601385,"gpt":0.405004672436912,"spread":0.2668459262767735,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01426066,0.003167314,0.01116152,0.001882596,0.0005086173,0.002604229,0.002080583,0.002372389,0.003847038],"category_scores_gemma":[0.02404121,0.001812861,0.04693476,0.00286633,0.000692187,0.001764128,0.002008617,0.003693127,0.0003515886],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001360645,"about_ca_system_score_gemma":0.0008511348,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006900612,"about_ca_topic_score_gemma":0.009053685,"domain_scores_codex":[0.9837651,0.01047133,0.001667808,0.002671781,0.0008835546,0.0005405629],"domain_scores_gemma":[0.9815674,0.01392992,0.002050906,0.00148109,0.0006506839,0.0003199101],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.01278825,0.00002048789,0.01113437,0.007782141,0.9641112,0.00005091878,0.00002558351,0.001060523,0.0002123267,0.0000845343,0.0003461019,0.002383597],"study_design_scores_gemma":[0.002449383,0.0003574497,0.01062163,0.0004903987,0.9841059,0.0000492664,0.0000251656,0.0008318983,0.0001084581,0.0003000482,0.0006347387,0.00002576155],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.1899657,0.7904147,0.009392736,0.0008109549,0.001329762,0.0003846101,0.005474308,0.0003105703,0.001916634],"genre_scores_gemma":[0.9450535,0.04714263,0.003176482,0.0009563396,0.0004174103,0.0003854811,0.001713798,0.0001621243,0.0009922542],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.01426066,"threshold_uncertainty_score":0.07541841,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3174841530","doi":"10.1038/s41416-021-01415-9","title":"Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer","year":2021,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Breast cancer; Medicine; Oncology; Hormone receptor; Cancer; Internal medicine; Oestrogen receptor; Clinical trial; Hormone","authors":[{"name":"Howard A. Burris","is_ca":false},{"name":"Arlene Chan","is_ca":false},{"name":"Aditya Bardia","is_ca":false},{"name":"J. Thaddeus Beck","is_ca":false},{"name":"Joohyuk Sohn","is_ca":false},{"name":"Patrick Neven","is_ca":false},{"name":"Debu Tripathy","is_ca":false},{"name":"Seock‐Ah Im","is_ca":false},{"name":"Stephen Chia","is_ca":true},{"name":"Francisco J. Esteva","is_ca":false},{"name":"Lowell L. Hart","is_ca":false},{"name":"Juan Pablo Zarate","is_ca":false},{"name":"Antonia Ridolfi","is_ca":false},{"name":"Karen Rodriguez Lorenc","is_ca":false},{"name":"Denise A. Yardley","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01697719221813876,"gpt":0.3431304860266393,"spread":0.3261532938085006,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003990642,0.0007911677,0.002537625,0.00035538,0.0002927537,0.001069232,0.000721678,0.001654257,0.007720426],"category_scores_gemma":[0.006796573,0.0004123046,0.003177018,0.0003659253,0.0009231889,0.001180052,0.0005082832,0.003795283,0.0008678607],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008152071,"about_ca_system_score_gemma":0.000578862,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007590583,"about_ca_topic_score_gemma":0.001976889,"domain_scores_codex":[0.9967723,0.00240251,0.0001543074,0.0002097031,0.0001828724,0.0002781995],"domain_scores_gemma":[0.9970226,0.001746379,0.0004768989,0.0002981315,0.0001551564,0.0003010178],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.9602513,0.0009309807,0.0008466549,0.0006405567,0.002194792,0.00003436547,0.00007498654,0.0009284051,0.001944815,0.0003597333,0.0008862237,0.03090717],"study_design_scores_gemma":[0.8343752,0.1317481,0.01880819,0.0003340079,0.003899115,0.0001612311,0.0001275224,0.001626606,0.001529027,0.002170212,0.005130408,0.00009047904],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9652604,0.02252426,0.0007657039,0.002042924,0.0007761075,0.0007264238,0.001328293,0.0001015948,0.006474304],"genre_scores_gemma":[0.9922951,0.002280418,0.0004660746,0.0008619856,0.0002947819,0.0004879688,0.0006864076,0.00003815087,0.002589075],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007720426,"threshold_uncertainty_score":0.02582747,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}